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1. Executive summary 
The Centre for Harm Reduction carried out a review of New Zealand’s Needle and Syringe 
Exchange Programme (NSEP) between April and September 2002.  The Review’s aim was 
to assess whether the NSEP is working in the most effective and efficient way possible 
within available resources. 
 
Methods 
Information was collected through a review of relevant literature, consultations with the 
NSEP stakeholders (the New Zealand Ministry of Health, the Pharmacy Guild of New 
Zealand, the Pharmaceutical Society of New Zealand, and Needle Exchange New Zealand) 
and other key agencies (including representatives of New Zealand’s law enforcement 
agencies), a survey of NE users, and a call for public submissions.  A major feature of the 
Review was the adaptation of methods and data used in Return On Investment In Needle & 
Syringe Programs In Australia (Health Outcomes International et al, 2002) to enable 
projections of the numbers of people living with HIV and HCV infections and produce 
cost/benefit estimates for New Zealand’s NSEP. 
 
Results 
Effectiveness 
Most of the scientific evidence clearly demonstrates that needle and syringe programmes 
worldwide are effective in reducing prevalence and/or incidence of HIV infection in 
injecting drug users.  New Zealand enjoys one of the lowest prevalences of HIV infection 
in IDUs (0.9%) among more developed nations, lower even than countries such as 
Australia and The Netherlands which have (arguably) employed more comprehensive and 
intensive needle exchange strategies.  It is estimated - by adapting the work of Health 
Outcomes International et al (2002) to suit New Zealand - that had the NSEP not been 
introduced, by the end of 2001 New Zealand would have had an extra 1,454 people living 
with hepatitis C, another 1,031 people living with HIV/AIDS, and an extra 20 people 
would have died following an HIV infection.  
A gradual decline has occurred in the prevalence of needle-sharing among New Zealand 
IDUs since the mid-80s, and the most recent survey data show a substantial reduction in 
prevalence of sharing (in the month prior to survey), from 50 in 1994 to six per cent in 
2002.  While proving a direct link between NSEP activities and behaviour is difficult, the 
implication is that the NSEP has contributed to a reduction in needle-sharing among IDU. 
The NSEP appears to be effective in reaching New Zealand’s IDUs, with less than 5% of 
survey respondents reporting frequent difficulty in obtaining injecting equipment.  Over 
90% of respondents perceived little or no difficulty with access due to distance from an 
outlet.  Nevertheless, the Review identified several regions which were under-serviced by 
NEs, including Auckland, Southland and the West Coast of the South Island.  There are 
also some concerns about the NSEP’s reach in terms of Maori and smaller ethnic groups. 
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Efficiency 
A cost/benefit analysis was conducted based on the estimated numbers of HIV and HCV 
infections prevented by NSEP introduction, annual treatment costs for people living with 
HIV or HCV disease, and annual investment in the NSEP.  Treating the estimated 1,031 
extra people living with HIV/AIDS and the estimated 673 diagnosed with chronic HCV by 
the end of 2001 (had the NSEP not been introduced) would have added $35,678,516 to 
New Zealand’s total healthcare outlay between 1988 and 2001, while total expenditure on 
the NSEP over that period was estimated at $10,644,588.  Thus the net benefit due to the 
NSEP – based on HIV and HCV treatment costs avoided between 1988 and 2001 – is 
$25,033,928.  Every $1 spent on New Zealand’s NSEP saved an estimated $3.35 in 
healthcare costs which would otherwise have accrued over the period of investment.  
Extending the projections forward until all the extra New Zealanders infected with HIV or 
HCV between 1988 and 2001 due to non-establishment of the NSEP were estimated to 
have died produces a cumulative net benefit of $202,274,686; using this approach, every 
$1 spent on the NSEP between 1988 and 2001 yields $20.00 in lifetime treatment costs 
avoided. 
Each needle and syringe distributed by New Zealand’s NSEP costs approximately $0.90, 
making the programme about as efficient in terms of unit cost as the Australian state of 
Victoria, but less efficient than the average of all Australian state programmes (NZ$0.74).  
Economies of scale and population density are probable explanations. 
 
Service delivery 
The NE users’ survey revealed that NE users were very happy with the service they 
received at NEs (96.5% selecting “good” or “very good”).  The most popular options for 
improving service were one-for-one (new for old) syringe exchange and out-of-hours 
electronic syringe dispensers. 
NE users were less satisfied with pharmacy exchange services, with 21.2% rating it as 
good or very good.  Better staff attitudes (towards IDUs) and lower prices of injecting 
equipment were the options favoured for improved service. 
 
Other issues 
In the consultations, nearly universal support was expressed for removing the anomaly of 
possession of injection equipment being an offence under the Misuse of Drugs Act [section 
13(1)(aa)] while a defence exists under the Health (Needles and Syringes) Regulations 
1998. 
One for one (new for old) needle and syringe exchange is the mode of service favoured by 
all NE staff.  Experience to date with one-for-one has been very positive in terms of 
increasing distribution of new and return of used equipment, and (anecdotally) reducing 
syringe re-use.  The Review’s survey of NE users found that IDUs attending NEs offering 
one-for-one exchange reported significantly lower prevalences of needle and syringe 
sharing and re-use than IDUs attending other NEs. 
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Electronic dispensers (vending machines) currently used by NEs in Auckland and 
Christchurch to provide after-hours service are working well, and were frequently 
nominated as a potential method of improving the reach of the NSEP. 
The concept of providing syringe disposal bins in public places was supported by many of 
those consulted as a way of enabling safer disposal and reducing the visible aspects of 
illicit drug use. 
Training for pharmacy staff and NE workers and volunteers was widely approved as a 
means of increasing the effectiveness and efficiency of the programme. 
 
Conclusion 
New Zealand’s NSEP is both effective and efficient, particularly with respect to prevention 
of HIV infections among injecting drug users. 
 
Recommendations 
1. That the effectiveness and efficiency of New Zealand’s NSEP be acknowledged. 
2. That New Zealand’s government and community recognise the vital role of the NSEP 
in preventing HIV infections. 
3. That consideration be given to opening a second peer-based NE in Auckland, to bring 
per-capita service coverage closer to the level which exists elsewhere in New Zealand. 
4. That consideration be given to improving NSEP coverage on the South Island’s west 
coast and Southland by opening branch NEs and/or upgrading and expanding existing 
pharmacy outlets. 
5. That consideration be given to increasing the reach of the NSEP by enabling and/or 
encouraging the provision of needle exchange services through existing health service 
infrastructure, such as Community Health Centres and Sexual Health clinics. 
6. That consideration be given to expanding the use of electronic dispensers at NEs to 
provide after-hours exchange services. 
7. That the costs and benefits that would result from the introduction of free one-for-one 
(new for old) needle and syringe exchange in New Zealand be formally investigated. 
8. That the crucial role of NE volunteers in New Zealand’s NSEP be affirmed, and that 
any resolution of the “reimbursement problem” must not jeopardise volunteers’ input 
to the programme. 
9. That New Zealand’s parliament approve the proposed amendment to the Misuse of 
Drugs Act which would remove the offence of possession of needles and syringes 
legally obtained through the NSEP.  
10. That the (perceived) problems of pharmacy staff attitudes towards needle exchange 
clients be addressed in a systematic way by the Ministry of Health, NENZ and the 
Pharmacy Guild; research into pharmacy exchange users’ perceptions of service would 
be a useful first step. 
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11. That the Pharmaceutical Society provide NEST with details of pharmacy closures, 
openings, and changes of ownership on a monthly basis. 
12. While return of used needles and syringes to NEs or pharmacies for destruction should 
remain first priority, NEs should address the issue of disposal of needles and syringes, 
by means other than return to NEs or pharmacies, in their IDU education activities in 
order to reduce visibility of needles and syringes in public places and risk of 
needlestick injury.   
13. That training modules for pharmacy staff be developed by NENZ and NEST in 
consultation with the Pharmacy Guild and Pharmaceutical Society, promoted by them, 
and delivered by NEST staff.  
14. That GP training in New Zealand include a component on aspects of illicit drug use, 
including the NSEP (its rationale and operation) and methadone maintenance 
programmes. 
15. That the Ministry of Health liaise with the NZMA about encouraging GPs to work with 
their local NE to provide improved access to testing, counselling and primary 
healthcare services. 
16. That basic training for NZ police include a short session on New Zealand’s harm 
minimisation policy and the NSEP.  NENZ should liaise with police to achieve this 
goal. 
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2. Introduction and Aim 
The Centre for Harm Reduction (CHR) was commissioned to review New Zealand’s 
Needle and Syringe Exchange Programme (NSEP) in March 2002.  (The terms of 
reference for the Review are shown in Appendix 1.)  A CHR team collated existing data, 
collected new data (via consultations with stakeholders, a survey of NSEP users, and a call 
for public submissions in major daily newspapers) and analysed it to produce this report.  It 
includes recommendations for action to improve the effectiveness of needle exchange 
services in New Zealand. 
 
2.1 Aim of the review 
To assess whether the NSEP is working in the most effective 
and efficient way possible within available resources. 
 
The key words in the aim were interpreted as follows: 
 
Effectiveness – is the NSEP achieving its stated objective(s)? 
Efficiency – is the NSEP achieving its stated objective(s) cost-effectively? 
 
2.2 Terminology 
On advice from the Ministry of Health, throughout this report the term ‘Needle and 
Syringe Exchange Programme’ (NSEP) is used to denote the entire system of provision 
and collection of injecting equipment that operates in New Zealand.  ‘Needle Exchange 
(NE) is used to mean any one of the (at the time of writing) 12 peer-based organisations 
which provides injecting equipment and associated services to people who inject drugs in 
New Zealand. 
All dollar amounts are in New Zealand dollars unless otherwise indicated. 
 
2.3 Report structure 
This report is organised by the key points contained in the terms of reference; it brings 
together the information gathered from all sources on each point in turn.  Thus, instead of 
describing the outcomes of the consultations in a single section (which would involve 
considerable repetition, as essentially the same points were covered in each), they are used 
in conjunction with other data to form conclusions on key questions. 
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3. Background 
 
3.1 The rationale behind Needle and Syringe Exchange Programmes 
The fundamental reason for the establishment of needle and syringe programmes is to 
reduce transmission of the Human Immunodeficiency Virus (HIV) between people who 
inject drugs, and hence reduce the rate of infection for the entire community.  Injection of 
illicit drugs using needles and syringes contaminated with HIV-infected blood is an 
extremely efficient way of transmitting the virus, which then moves into the non-injecting 
population via unprotected sexual contact.  In the United States, injecting drug use and 
IDUs’ sexual activity accounts for approximately half of all new HIV infections each year 
(Holmberg, 1996).  Needle and syringe programmes seek to interrupt HIV transmission by 
enabling IDUs to inject with sterile equipment, collecting used equipment for safe disposal, 
and educating IDUs about preventing infections.  The first needle and syringe programme 
opened in Amsterdam in 1984 (van den Hoek et al, 1989; since then programmes have 
been established in developed and developing countries the world over. 
 
3.2 Establishment of NSEP in New Zealand 
Needle exchange became possible in New Zealand through the introduction of the Health 
(Needles and Syringes) Regulations 1987 (later replaced by the Health (Needles and 
Syringes) Regulations 1998).  The regulations allow for the sale of needles and syringes to 
injecting drug users.  The programme allows pharmacists, medical practitioners and other 
authorised representatives to provide clean needles and syringes.   
The strategies of the NSEP are: 
• The sale and distribution of new (sterile) injection equipment. 
• Safe disposal of used needles and syringes. 
• Free distribution of safer sex products to NSEP clients. 
• Provision of clear simple messages about the transmission of diseases and safer drug 
use techniques to every person using the NSEP. 
The NSEP is based on a philosophy of problem limitation; that is to reduce as far as 
possible the potential harm resulting from injecting drug use rather than attempting to 
curtail the activity itself.  Problem limitation aims to modify behaviour to minimise the 
spread of HIV and other blood-borne diseases.  The NSEP, while not condoning the use of 
illegal drugs, accepts that drug use continues to occur despite its legal sanctions. 
 
3.3 The context of New Zealand’s NSEP 
Because an NSEP is a response to a public health problem directly associated with 
injection of illicit drugs, it is important to understand the wider context – legal, drug use, 
and public health aspects - of NSEP in New Zealand.   
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3.3.1 Drugs 
Heroin imported from Asia – the mainstay of drug injectors in Europe, Australia and North 
America – has only briefly (in the mid-1970s) been widely or reliably available in New 
Zealand (Kemp, 1996).  As a result, since the early 1980s New Zealand’s injecting drug 
users (IDUs) have been injecting prescribed opiates - such as methadone and morphine - 
diverted from their original licit sources, and producing their own injectable opiates.  
These include ‘homebake’, made from over-the-counter painkillers containing codeine; 
morphine sulphate tablets (prescribed for serious pain relief); and in season, opium 
harvested from locally-grown poppies.  More recently, New Zealanders have begun 
converting pseudoephedrine extracted from commercial cough and cold preparations to 
methylamphetamine.  This characteristic of self-reliant manufacturing in the absence of 
imported opiates and amphetamines has shaped the New Zealand IDU culture into a 
peculiarly underground one.  Street drug markets or ‘scenes’ like those which exist in the 
major cities of other nations are unknown.  The lack of street drug scenes means drug 
problems are much less visible in New Zealand than elsewhere – injecting in public and 
publicly discarded injecting paraphernalia are rare (Kemp, 1996).  The apparent recent 
increase in amphetamine use in New Zealand may alter this picture, producing more 
chaotic and event-associated injecting (Field and Casswell, 1998, cited in Brunton, 2002; 
Henderson C and Nimmo S, pers comm., cited in Brunton, 2002). 
 
3.3.2 Legal environment 
Needle exchange was made possible in New Zealand through the introduction of the 
Health (Needles and Syringes) Regulations 1987, which allowed the sale of needles and 
syringes to injecting drug users provided their sale is part of the NSEP.  The regulations 
(later replaced by Health (Needles and Syringes) Regulations 1998) also create a legal 
defence to the charge of possession of injection equipment, which remains an offence 
under the Misuse of Drugs Act [section 13(1)(aa)].   
Under the regulations a person can be charged and prosecuted for possession of needles 
and syringes obtained under the NSEP but – if he or she can prove that the equipment was 
legally purchased under the NSEP - cannot be found guilty.  (This apparent anomaly 
received a good deal of attention in the Review and is referred to several times in this 
report.) 
 
3.3.3 Public Health 
New Zealand’s NSEP was a response to a feared epidemic of HIV among injecting drug 
users in the 1980s, an epidemic which – unlike in the United States and some other western 
countries - did not eventuate.  There is considerable ecological evidence that countries with 
needle exchange programmes have lower HIV prevalence and incidence among IDUs than 
countries without (see section 6.1).  Whatever the reason, it is certainly true that New 
Zealand enjoys one of the lowest rates of HIV infection among IDUs in the world (see 
section 6.2). 
The hepatitis C virus (HCV) is at substantially higher prevalence among New Zealand’s 
IDUs than HIV, and will continue to be the major viral threat to their health and a cause of 
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substantial healthcare costs.  HCV is more efficiently transmitted than HIV, and this fact, 
combined with a much higher background prevalence and historical endemicity in the IDU 
population, makes it much more difficult to control (Crofts et al, 1999).  With prevalence 
among NSEP users measured at 72-84.2% among IDUs in opioid treatment (Judson, 1999; 
Carter et al, 2001) and 53% among IDUs tested at NEs (Kemp and MacDonald, 1999), 
HCV has rightly become the focus of the programme’s blood-borne virus (BBV) 
prevention efforts. 
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4. Methods 
 
4.1 Personnel 
The review team consisted of Dr Campbell Aitken (team leader - CHR, Burnet Institute, 
Australia), Helen Fraser (research assistant - CHR, Burnet Institute, Australia), Dr Nick 
Crofts (technical director - CHR, Burnet Institute, Australia), and Dr Cheryl Brunton (New 
Zealand collaborator - Department of Public Health & General Practice, Christchurch 
School of Medicine and Health Sciences).  Brendon Baker of the New Zealand Ministry of 
Health was our liaison officer and provided support in the form of contacts and data. 
A steering group was formed to provide expert advice and direction to the review team.  It 
included Nick Crofts, Owen Westcott (NSW Department of Health), Robert Kemp 
(Queensland Health – formerly manager of the Drugs and Health Development Project, 
Wellington, New Zealand), Dr Greg Dore (National Centre for HIV Epidemiology and 
Clinical Research (Australia), and Campbell Aitken. 
 
4.2 Data collection 
The review team used four distinct approaches to collect information – a literature review, 
consultations with key agencies, a survey of NE users, and a call for public submissions. 
 
4.2.1 Literature review 
All available relevant material – published and unpublished, official reports and scientific 
articles – was collated and evaluated.  Data which could be used to evaluate the 
performance of the NSEP were also collected for later analysis.  All published material 
used in this review is cited in the text and listed in the References section. 
 
4.2.2 Consultations 
The Review team leader held face to face consultations with the stakeholders of the NSEP 
(the New Zealand Ministry of Health, the Pharmacy Guild, the Pharmaceutical Society, 
and Needle Exchange New Zealand) and other key agencies in four New Zealand cities 
between the 13th and 17th of May 2002.  Representatives - usually the managers, but 
frequently including other staff, volunteers, and trustees - of nine of the 12 peer-based 
Needle Exchange programmes (NEs) were consulted in four sessions in Auckland, 
Wellington, Christchurch and Dunedin.  Table 4.1 shows the consultation schedule and 
gives details of participation. 
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Table 4.1.  People consulted and their roles in or relationships to the NSEP. 
 
Date Consultation host People consulted 
May 13th Rodger Wright Centre, 
Christchurch 
Maggie Treweek (RWC Manager), Charles 
Henderson (NENZ – former RWC manager), Ian 
Smith (RWC Trustee), Jan Thomas (employee, 
Timaru NE), Lyn Waller (Manager, Nelson NE) 
May 13th NENZ, Christchurch Charles Henderson (National coordinator), Patsy 
Davison (South Island coordinator) 
May 13th Hepatitis C Resource Centre, 
Christchurch 
Bill Jang (Manager) 
May 14th DIVO, Dunedin  Hilary Lawrence (DIVO Community Worker), 
Gregor Richardson (Pharmacy Support Worker and 
Exchange Assistant), Donald Reid (Office 
Administrator), Fyfe, Rob, Steve (volunteers), Peter 
(client), Peter Barron, Stephen Farquhar, Paul 
Fawcett, Jimmy (DIVO trustees), Rosemary Friend 
(sessional GP) 
May 15th Pharmaceutical Society, 
Wellington 
Euan Galloway (Manager, Pharmacy Practice and 
Legislation) 
May 15th Ministry of Health, 
Wellington 
Brendon Baker (Analyst - National Drug Policy), 
Michael Baker (previous NSEP reviewer) 
May 16th New Zealand Police Paul Marriott-Lloyd (Strategic Policy Group), 
Richard Schurr (National Drug Intelligence Bureau), 
Gary Knowles (National Bureau of Criminal 
Intelligence), Mike Arnerich (Wellington Metro 
Organised Crime Unit) 
May 16th Drugs Project, Wellington 
(NE) 
Kelley Auerbach (manager), Drew Thomas 
(manager, Palmerston Nth NE), Sandy (manager, 
Napier NE), David (Palmerston Nth employee), 
Simon (volunteer) 
May 17th Pharmacy Guild, Auckland Maree Jensen (Member of the Guild National 
Council) 
May 17th New Zealand AIDS 
Foundation, Auckland 
Kevin Hague (Director) 
May 17th ADIO Trust, Auckland (NE)  Karen Blacklock (Manager); Gerry MacPhail (NINE 
manager); Garth (employee), Bob (volunteer) 
 
The Review team leader held an unscheduled telephone conversation with Dr Geoff 
Robinson (an opioid treatment specialist located in Wellington) at the instigation of Euan 
Galloway (Pharmacy Guild), and another with Dr Rosemary Friend (a GP who offers 
regular counselling and primary healthcare sessions at DIVO, Dunedin).  These 
opportunities for medical perspectives on the NSEP were greatly appreciated as New 
Zealand’s general practitioners, the Royal New Zealand College of GPs and the New 
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Zealand Medical Association, had been invited to provide representatives to participate in 
the Review, but both declined. 
In late June, the Review team leader had a telephone conversation with Dr Richard Meech, 
chair of the AIDS Medical and Technical Advisory Committee (AMTAC). 
 
4.2.3 Survey of NE users 
In order to include the views of the ‘clients’ of New Zealand’s NSEP, in consultation with 
Dr Cheryl Brunton and NE managers a brief questionnaire (see Appendix 2) was 
developed for use in a survey of users of NE users.  The questionnaire was printed on both 
sides of a single page and was designed for respondents to complete independently; 
participation was voluntary and anonymous, questionnaires being identifiable only as 
having been completed at a particular NE.  The questionnaire focused on users’ 
perceptions of the NSEP (NEs and pharmacies) and its operation.   
Dr Brunton printed the questionnaires and sent the NEs quotas based on their needle and 
syringe outputs for 2000 (NENZ Trust, 2000).  The survey ran between the 17th and 29th of 
May 2002, and the views of 316 NE users were canvassed.  Completed questionnaires 
were returned to Dr Brunton, copied, and posted back to Melbourne for analysis. 
 
4.2.4 Call for public submissions 
A call for public submissions (see Appendix 3) was placed as a public notice in The 
Dominion, The New Zealand Herald, The Press and the Otago Daily Times on Saturday 
19th April 2002 and The Dominion, The New Zealand Herald and The Press on Saturday 
26th April 2002.  People wishing to make a submission could obtain the Review’s terms of 
reference by writing, telephoning or faxing the Review’s Ministry of Health liaison officer, 
or by copying or downloading them from the Centre for Harm Reduction’s website.   
No submissions were received by the closing date of Friday 7th June 2002.   
 
4.3 Estimating the NSEP’s effect on HIV infections among IDU 
A study carried out for the Commonwealth Department of Health and Ageing (Australia) 
entitled Return On Investment In Needle & Syringe Programs In Australia has recently 
been released (Health Outcomes International et al, 2002).  The authors made projections 
of the annual numbers of HIV infections which would have occurred among IDUs without 
the introduction of Australia’s needle and syringe programs (NSPs), and subtracted from 
these from estimates of HIV infections occurring among IDUs with NSPs in place, to 
arrive at estimates of HIV infections prevented by NSPs.  These figures were used in 
conjunction with HIV treatment costs and NSP expenditure to estimate annual returns on 
investment (ROI) in Australia’s NSPs.  The methods and data employed in the ROI study 
were made available to the Centre for Harm Reduction so the process could be adjusted to 
produce equivalent estimates for New Zealand.  The fundamentals of the Australian study 
and how it was adapted to suit New Zealand’s parameters are briefly described in the 
following paragraphs. 
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4.3.1 Methods used in the Australian ‘Return On Investment’ study re HIV 
In order to produce estimates of the annual costs of treating the HIV infections which 
would have occurred without NSEP introduction in Australia, the following data (in many 
cases, also estimated) were required: 
• annual HIV prevalences among Australian IDUs 
• the number of IDUs 
• past HIV incidence among IDUs 
• annual treatment costs for each HIV disease stage. 
HIV prevalence among IDUs in Australia between 1980 and 2000 was based on the 
estimated numbers of IDUs living with HIV and estimates of the numbers of IDUs in 
Australia.  The number of dependent heroin users in Australia in 1997 was assumed to be 
75,000 (Hall et al, 2000), and assuming a constant net 8% increase in dependent heroin 
users per year gave a reasonable fit to the estimated numbers for the previous 20 years.  To 
allow for injecting of other drugs, the total number of regular IDUs was assumed to be 
33% greater than the number of dependent heroin users (ie 100,000 regular IDUs in 1997 
(Law 1999).  The number of occasional IDUs was assumed to be 175,000 in 1997 (ibid) 
with the same annual percentage increases.   
Health Outcomes International et al’s (2002) estimates of past HIV incidence and future 
AIDS incidence as a result of injecting drug use were obtained using back-projection 
methods.  Observed AIDS incidence data, adjusted for reporting delay, and knowledge of 
the rate at which HIV infected people progress to AIDS were used to reconstruct the likely 
pattern of past HIV incidence, thereby enabling projection of future AIDS incidence.  
HIV incidence was fixed at 20 cases per year from 1994 onwards on the basis of the 
number of HIV diagnoses and diagnoses of newly acquired HIV infection reported to the 
National HIV Database.  This incidence rate was consistent with the estimated HIV 
incidence obtained from the back-projection analyses.  Estimates of the number of people 
living with HIV infection by disease stage were based on the estimated pattern of past HIV 
incidence.  
All the data referred to above enabled Health Outcomes International et al to estimation of 
annual numbers of IDU living with HIV by disease stage, and of numbers of HIV 
infections by disease stage which would have occurred without NSP introduction.  In their 
analyses, HIV incidence due to IDU was assumed to cease in 2001, and estimates were 
projected forward until all people infected with HIV to 2001 were estimated to have died.  
For each year, the differences between the two sets of estimates (representing numbers of 
HIV-infected IDUs prevented or caused by NSP introduction) were multiplied by the 
annual treatment costs for people in three stages of HIV disease (early = CD4 count less 
than 500, advanced = CD4 count more than 500, and AIDS) and the products totalled to 
give an annual gross cost or saving.  To account for savings being more valuable now than 
in the future, estimated treatment costs avoided after 2001 were discounted back to that 
date at an annual rate of 5%.   
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4.3.2 Adjustments for New Zealand 
Modifying the Australian estimates to predict the numbers of HIV infections which would 
have occurred among New Zealand’s IDUs without the introduction of the NSEP required 
IDU population estimates, the NSEP start-up date, and HIV surveillance data. 
 
4.3.2.1 Rationale for using Australian HIV data to model New Zealand’s 
Australia and New Zealand are similar in many ways, and maintain close economic, 
political and cultural links.  Our British colonial pasts, our majority Anglo-Celtic 
populations, our very similar modes of life and of course our close geographical alignment 
have for many years facilitated the exchange of large numbers of temporary and permanent 
migrants.  These similarities extend to the two countries’ profiles in terms of drug-related 
HIV epidemiology and health policy responses.  New Zealand established needle and 
syringe programs in the late 1980s (a year after Australia) with the aim of avoiding the 
HIV epidemics in injecting drug users already underway in the United States and Europe.  
As will be shown in later sections, HIV prevalences among Australian and New Zealand 
IDUs have never reached the levels experienced elsewhere in the world, and in the 21st 
century remain very low by world standards.  Accordingly, perhaps the best justification 
for applying a simple adjustment of Australian HIV projections to the New Zealand 
situation is the historical consistency of HIV diagnosis data across the two countries.  The 
correlation between the annual numbers of HIV diagnoses in Australian and New Zealand 
IDUs, 1990-2000, is 0.792 (Pearson’s correlation), significance = 0.004, meaning the two 
trends are strongly related.   
 
4.3.2.2 Data used to create HIV projections for New Zealand 
In 2000, Nesdale et al (2000) produced estimates of the size of New Zealand’s IDU 
population to facilitate projections of the prevalence and future impact of hepatitis C in 
New Zealand.  Estimates were based on previous New Zealand studies and assumptions 
about the pattern of injecting drug use over time, and compared with estimates based on 
Australian data, adjusted for New Zealand population size.  Nesdale et al’s preferred 
estimate was 15,000 regular IDU and 7,000 occasional IDU, giving a total IDU population 
of 22,000 (range 20,000-24,000) in New Zealand in 2000.  To obtain a 2001 figure, the 
annual 8% net increase used by Health Outcomes International et al (2002) for Australian 
IDUs was assumed to apply in New Zealand.  Thus, for 2001, the estimated IDU 
population of New Zealand was 22,000 * 1.08 = 23,760.  This figure was divided by the 
total estimated Australian IDU population for 2001 (projected forward at 8% per annum) 
of 340,122, and the resulting ratio applied to Health Outcomes International et al’s 
estimates of Australians who acquired HIV through injecting drug use to generate 
corresponding estimates for New Zealand.  Happily (for our purposes), this process results 
in an estimate of cumulative IDU-acquired HIV infections in New Zealand by end 2001 of 
47, exactly matching the total number of diagnosed infections (Eberhart-Phillips, 2002).  
New Zealand’s NSEP began operating in 1988.  Hence, any effect of the NSEP on HIV 
prevalence among IDUs would be apparent from 1989 onwards.  The New Zealand-
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adjusted data were shifted a year forwards to account for the delay over implementation in 
Australia. 
A further adjustment was made to the estimates of HIV cases prevented by NSEP 
introduction to try to account for differences between Australia’s and New Zealand’s IDU 
scenes.  In New Zealand imported opiates are rare and few readily injectable drugs are 
available, there are no street drug scenes or markets and (plausibly) less social mixing 
among IDUs as a result; therefore it seems appropriate to be relatively conservative in 
estimating HIV incidence without the NSEP.  (As actual HIV diagnoses to 2001 match our 
estimate, there is no incentive to adjust our estimates of HIV incidence with the NSEP.)  
These differences between estimated HIV cases and deaths per annum with and without 
NSEP introduction, calculated by adjusting the Australian ROI data tables (Health 
Outcomes International et al (2002), were regarded as the upper bounds on the NSEP’s 
prevention effect.  As no meaningful way exists to create confidence intervals on these 
projections, it was decided that the best course was to be consistent with the procedure 
used with respect to HCV (see section 4.4.2).  Therefore, the “middle-bound” estimates 
were calculated at 1/1.74 and the lower bounds at (1-0.74)/1.74 of the adjusted ROI 
model’s results (so that the upper bound estimates is 74% greater than the “middle” and the 
lower bound estimates are 74% smaller).  Note that these bounds do not provide any basis 
for evaluating the statistical significance of the results, rather they enable an apprehension 
of the sensitivity of projections to variation in the numbers of infections prevented. 
Annual treatment costs are converted into New Zealand dollars at an average exchange rate 
of $A1 = 1.2$NZ.   
 
4.4 Estimating the NSEP’s effect on HCV infections among IDU 
Health Outcomes International et al’s (2002) study, described in more detail in section 4.3 
with respect to HIV, included projections of the annual numbers of HCV infections with 
and without the introduction of NSPs in Australia, and estimated annual returns on 
investment due to the NSP’s effects on HCV transmission.  The methods used to do so, and 
the adjustments made to adapt Health Outcomes International et al’s data to a New Zealand 
context, are briefly explained below. 
 
4.4.1 Methods used in the Australian ‘Return On Investment’ study re HCV 
In order to produce estimates of the annual costs of treating the HCV infections which 
would have occurred without NSEP introduction in Australia, Health Outcomes 
International et al (2002) made the following assumptions: 
 
• The HCV incidence rate in regular IDUs was 18% per annum between 1960 and 
1985, after which it decreased linearly to 13% in 1989 and continued to decrease at 
that rate thereafter. 
• The HCV incidence rate in occasional IDUs was 20% of that in regular IDUs. 
• Starting or stopping injecting, or occasional IDUs becoming regular, was 
independent of HCV status. 
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• HCV incidence due to receipt of infected blood or blood products was 15% of HCV 
incidence in IDUs until 1983, after which it gradually decreased due to the 
introduction of donor self-deferral related to injecting drug use, and was zero from 
1990 due to blood donation screening. 
• HCV incidence through other non-IDU-related transmission routes (such as needle 
stick injuries in health care workers, or tattoos) was 10% of HCV incidence in IDUs 
between 1987 and 1997 (reflecting the data on risk factors for recent incident HCV 
infections).  Before 1987 it increased linearly to 20% of HCV incidence in IDUs in 
1977, then stayed at this absolute number of infections per year (again broadly 
consistent with data on risk factors for prevalent HCV infections, and for people with 
HCV infection attending liver clinics). 
• The number of HCV infections between 1950 and 1960 was held constant at a low 
level proportional to the modelled HCV incidence among IDUs. Any HCV infections 
prior to 1950 were assumed to have negligible effect on estimates and projections, 
and were not modelled. 
Health Outcomes International et al’s (2002) modelling of HCV incidence in Australian 
IDUs corresponds to a gradual increase in HCV prevalence among regular IDUs until the 
mid- to late-1980s, succeeded by a steady decline to around 52% HCV prevalence in 2000.  
NSPs were assumed to have reduced HCV prevalence among IDUs from 1988 onwards. 
HCV prevalence in the absence of NSPs was modelled by assuming that HCV prevalence 
would have remained at the 1988 level from that year onwards. 
To cost the effect of NSPs in reducing the number of people living with HCV, estimates of 
the reduction in the number of people living with HCV by disease stage were made by 
subtracting the estimates obtained with NSPs from the corresponding estimates without 
NSPs (ibid), adjusting the remainder for under-diagnosis, and multiplying by the 
appropriate treatment costs.  To account for money being more valuable now than in the 
future, treatment costs of HIV or HCV infections avoided are discounted back to 2001, at 
an annual rate of 5%.  
 
4.4.2 Adjustments for New Zealand 
Adjustments similar to those used for HIV (see section 4.3.2.2) were applied to produce 
HCV projections for New Zealand from the ROI data (Health Outcomes International et al, 
2002).  Nesdale et al’s (2000) estimate of the size of New Zealand’s IDU population was 
projected forward to 2001 and divided by the corresponding figure for Australian IDUs, 
and the resulting ratio (23,760/340,122) applied to Health Outcomes International et al’s 
estimates of Australians who acquired HCV through injecting drug use with and without 
NSP introduction.  This procedure resulted in an estimate of 13,033 people living with 
HCV acquired via IDU by the end of 2000 – only 51% of Nesdale et al’s estimate of 
25,200 New Zealanders living with HCV acquired by all routes.  If it is assumed that 90% 
of all HCV infections in New Zealand are IDU-acquired, then Nesdale et al’s IDU-
acquired figure for 2000 becomes 22,680, which is 74% greater than the ROI-derived 
estimate for 2000.  Accordingly, it was decided to create upper-bound estimates by scaling 
the projection upward by 74% so the estimate for 2000 matched Nesdale’s (adjusted) 
22,680.  Lower bounds were created by multiplying the ROI-derived estimates by (1-0.74).  
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This had the effect of making the results more conservative, which was necessary to try to 
account for the differences between Australia’s and New Zealand’s IDU scenes that are 
likely to mean lower rates of transmission in New Zealand in the absence of the NSEP. 
Estimated annual treatment costs were converted into New Zealand dollars at an average 
exchange rate of $A1 = 1.2$NZ.   
 
4.4.2.1 Rationale for using Australian HCV data to model New Zealand’s 
Essentially the same arguments apply here as for HIV (see section 4.3.2.1).  The 
fundamental similarities and geographical closeness of Australia and New Zealand and 
very similar drug-related HCV epidemiology and health policy responses have been used 
by other authors as an argument for the validity of adjusting Australian data streams to 
model those in New Zealand.   
 
4.5 Cost/benefit analysis 
The return on investment in New Zealand’s NSEP due to prevention of HIV and HCV 
infections combined was calculated using the method applied in the Australian ROI study 
(Health Outcomes International et al, 2002).   
• The estimated cumulative costs of treatment for people who acquired HIV or HCV 
through IDU between 1988 and 2001 with the NSEP in place 
are subtracted from: 
• the cumulative estimated treatment costs for people who would have acquired HIV 
or HCV through IDU between 1988 and 2001 without NSEP introduction 
leaving the cost of treatment for HIV or HCV infections avoided by the NSEP, from which 
is subtracted: 
• New Zealand’s investment in the NSEP between 1988 and 2001 
to obtain a net return on investment, which can also be expressed as dollars saved per 
dollar invested.   
Costs or benefits are reported for the period 1988 to 2001 (meaning only estimated 
treatment costs avoided between and including those years are counted), and also by 
counting treatment costs avoided until all the extra people who would have acquired HIV 
or HCV through IDU in that period without NSEP introduction are estimated to have died.  
The annual and cumulative investments in the NSEP for 1998-2001 remain unchanged. 
 
4.6 NE users’ survey data 
Questionnaire data were entered into a Filemaker Pro 4.0 database, then exported to SPSS 
for analysis.  Some descriptive statistics for the NE users who completed the questionnaire 
are given below; results relating to the Review’s key questions (effectiveness of the NSEP, 
efficiency of the NSEP, etc) are dealt with in the appropriate sections of this report. 
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4.6.1 The sample of NE users 
Three hundred and sixteen people completed questionnaires during visits to the 12 NEs in 
mid-May 2000.  Of 311 respondents who provided their gender, 124 (39.9%) were female.  
Mean age (298 responses) was 32.3 years (range 17-60), 32.9 for males and 31.3 for 
females.  Three hundred and three respondents specified their ethnic background, of whom 
38 (12.5%) described themselves as Maori or New Zealander/European and Maori; 258 
(85.1%) specified New Zealand/European ethnicity; the remaining 7 individuals were of 
Asian (5), Australian (1) and Pacific Islander (1) ethnicity. 
 
4.6.1.2 Drugs injected 
Respondents were asked to nominate the drug they had injected most often in the month 
prior to completing the questionnaire, but instead many listed all the drugs they had 
injected in that period.  The result is a list of drugs injected that is incomplete for many 
survey participants (those who answered the question correctly), but nevertheless captures 
the most important drugs injected by all.  One hundred and eighty-two reported injecting 
MST or morphine (57.6%), 102 (32.3%) methadone, 81 (25.6%) speed, 39 (12.3%) Ritalin, 
34 (10.8%) homebake, 11 (3.5%) benzodiazepines, and 2 (0.6%) opium (percentages do 
not add to one hundred as many participants reported injecting multiple drugs).  The very 
small number citing opium should be viewed in the light of the timing of the survey – 
opium poppies are harvested from approximately November to March in New Zealand, 
while the survey was conducted in mid-May, when stocks of drugs are very likely to have 
been very low (Robert Kemp, pers comm). 
 
4.6.1.3 Injecting frequency 
Recent injecting frequency was measured on a categorical scale, the categories being 1 or 
less often, 2-3, 4-7, 8-13, and 14 or more times per week.  The modal category, with 79 
(25.2%) of 313 respondents to this question, was 14 or more times per week; 53 (16.9%) 
injected 8-13 times, 67 (21.4%) 4-7 times, 78 (24.9%) 2-3 times, and 36 (11.5%) injected 
once or not at all.  Taking the halfway mark of each category (and 0.5 injections per week 
for the first and 17 for the last) gives a mean frequency of 8.0 injections per week for the 
sample. 
 
4.6.1.3 NE use 
The frequency with which IDUs obtained needles and syringes from NEs was measured on 
a categorical scale, the categories being 1-2, 3-4, 5-8, 9-12, and 13 or more times in the 
month prior to the survey.  The modal category, with 87 (27.5%) of 316 respondents to this 
question, was 13 or more times per month; 36 (11.4%) visited 9-12 times, 74 (23.4%) 5-8 
times, 79 (25.0%) 3-4 times, 33 (10.4%) once or twice, and 7 (2.2%) did not get needles 
and syringes from an NE in the month prior to the survey.  Taking the halfway mark of 
each category (and 15 times per month for the last) gives a mean frequency of 7.9 NE 
visits per month for the sample. 
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4.6.1.4 Pharmacy use 
The frequency with which IDUs bought needles and syringes from pharmacies was 
measured in the same way as NE visits.  The modal response was zero times in the past 
month, given by 188 (59.5%) of the 316 respondents to this question.  Ten respondents 
(3.2%) bought needles and syringes from a pharmacy 13 or more times, 2 (0.6%) visited 9-
12 times, 13 (4.1%) 5-8 times, 30 (9.5%) 3-4 times, 73 (23.1%) once or twice in the past 
month.  Taking the halfway mark of each category (and 15 times per month for the last) 
gives a mean frequency of 1.5 visits per month for the sample. 
 
4.6.2 Comparisons with the Consumer Survey, 2000 
In 1999 Needle Exchange New Zealand (NENZ) surveyed 435 NE clients (NENZ Trust, 
2000) using methods similar to those used in the Review’s survey.  NENZ’s survey is 
henceforth referred to as the Consumer Survey. 
When the two samples are compared, several differences are apparent.  The Review 
sample contains a significantly higher proportion of female IDUs (39.9% vs. 31%, 
p<0.01), and its respondents are slightly older than the Consumer Survey’s, although 
probably not significantly so (this cannot be tested without access to Consumer Survey raw 
data).  No differences exist in the ethnic makeup of the samples, both being dominated 
(85+%) by European/New Zealander backgrounds.  
The Review sample contains a significantly higher percentage of opiate injectors than the 
Consumer Survey (89.9% vs. 75%, p<0.001), a surprising result given the general 
recognition of increased prevalence of amphetamine injecting in New Zealand over recent 
years.  A possible explanation is that 140 Consumer Survey questionnaires completed at 
the Rodger Wright Centre (Christchurch) and NICHE (Nelson) were lost prior to analysis, 
and opiate use has historically been much more prevalent in the South Island (NENZ Trust, 
2000); thus the Consumer Survey very probably underestimated the prevalence of opiate 
use among New Zealand IDUs. 
 
4.6.3 Other comments on survey sample 
Recruiting IDUs through NEs and asking questions about satisfaction with NE and 
pharmacy-based exchange service is obviously less than ideal.  Such a process excludes 
people who only ever obtain injecting equipment from pharmacies and biases the sample 
towards people who preferentially use NEs over pharmacies.  Another bias introduced by 
our recruiting method is the under-sampling of people who visit NEs less frequently than 
they would like (or not at all) due to distance or transport problems, concerns about 
anonymity, unsuitable opening hours or financial difficulty.   
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5. New Zealand’s Needle and Syringe Exchange Programme 
 
5.1 NSEP Structure 
New Zealand’s NSEP operates by the New Zealand Ministry of Health contracting drug 
user groups, constituted as charitable trusts, to run individual NEs as separate businesses.  
The NSEP has four stakeholder groups - the Ministry of Health, Needle Exchange New 
Zealand (NENZ), the Pharmacy Guild, and the Pharmaceutical Society. 
NENZ is the peak body for the peer-based NEs in New Zealand.  NENZ is run by a board 
consisting of the NE managers and is responsible for: 
• national coordination of needle exchange to enhance service delivery  
• liaison with the Ministry of Health, and provision of feedback to the NEs 
• pharmacy liaison and recruitment of new pharmacies to the NSEP 
• liaison with non-pharmacy outlets (such as the New Zealand Prostitute’s 
Collective) and allied organizations (such as the New Zealand AIDS Foundation) 
• production and circulation of a newsletter for NENZ members 
• publication of an annual directory of exchange outlets, an annual review of sales, 
and conducting a bi-annual consumer survey 
• production of health education resource materials 
• development of national purchasing arrangements 
• following international developments in needle exchange and maintaining 
international linkages  
• Organization of at least two NSEP stakeholder meetings per annum. 
NENZ is also the controlling stakeholder in the Needle Exchange Services Trust (NEST), 
which supplies needle and syringe collection and destruction services throughout New 
Zealand on a commercial basis.  Profits are fed back into NENZ projects. 
 
5.2 Modes of operation 
There are currently around 200 outlets in the Needle and Syringe Exchange Programme, of 
two main types – NEs and pharmacies.  Other sources of injecting equipment exist to fill 
gaps in coverage – 10 ‘alternate outlets’ (such as the New Zealand Prostitute’s Collective), 
8 outreach workers and 2 general practitioners.  In 2000, NEs (7% of the total number of 
outlets) were responsible for 64% of sales (New Zealand Ministry of Health, 2002).   
 
5.2.1 NEs 
There were 12 NEs operating in New Zealand in May 2002. 
Needle Exchange in New Zealand is largely run on a user-pays basis.  At most outlets (all 
pharmacies and most NEs), drug-users must purchase new injection equipment; however, 
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NEs in Palmerston North, Napier and Wellington currently offer a free one for one (new 
for old) needle and syringe exchange service.  
Prices for injection equipment are set independently by the outlets.  Prices for a single 
needle and syringe are generally around $1; discounts off the price of new fits (generally 
around 20c) are offered by most outlets to encourage consumers to return used injection 
equipment.   
NEs offer a complete range of needles and syringes as well as more unusual items such as 
butterflies. They also stock a range of accessories such as filters, sterile water, swabs and 
safer sex supplies.  New Zealand’s NEs are run by drug users, for drug users; therefore 
they are able to offer detailed advice about safer drug use and safer sex as well as referrals 
to other drug-user-friendly health services.  Some NEs provide clients with primary 
healthcare services. 
All dedicated NEs are able to offer courier delivery of new injection equipment throughout 
New Zealand.  All goods dispatched by courier must be accompanied by printed 
educational material and details of safe disposal methods for used injection equipment. 
 
5.2.2 Pharmacies 
There were 185 pharmacies participating in the NSEP in May 2002, and 940 pharmacies in 
New Zealand in all (Euan Galloway, Pharmaceutical Society, pers comm.). 
Pharmacies can offer needle exchange services at two levels.  Level 2 outlets sell single 
fits, as well as packs, and stock filters, sterile water and swabs.  They usually stock four or 
five of the more popular fit types.  Most Level 2 outlets are higher volume pharmacies with 
strong demand for needle exchange services.  Level 1 outlets sell only packs of 10 26-
gauge 1/2" needles with 3ml syringes.  All pharmacies are required to either sell needles 
and syringes or direct customers as to where they could obtain them.  
 
5.2.3 Other outlets 
Needle exchange services are offered by public health, sexual health or drug treatment 
services in some areas of New Zealand where no NEs and no or few pharmacy outlets 
exist.  These outlets usually have limited opening hours.  
The New Zealand Prostitutes’ Collective (NZPC) offers full needle exchange services at all 
of their offices to complement their services for sex industry workers and their clients. 
These services are open to all, whether involved in the sex industry or not.  
 
5.2.4 Electronic Dispensers 
Three electronic dispensers (vending machines) provide after hours access to injection 
equipment in New Zealand.  At the Sexual Health Centre at Auckland Hospital, a machine 
operates during office hours, selling packs (effectively the same as a level 1 pharmacy 
outlet).  At ADIO Trust (7A Maidstone St Auckland) and the Rodger Wright Centre (10 
Liverpool St Christchurch), the vending machines offer a wide range of stock and operate 
from 10pm to 10am everyday (ie, when the NEs are closed).  The two NE-based machines 
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are responsible for approximately 15% of total needle and syringe distribution at each 
exchange (Maggie Treweek and Karen Blacklock, pers comm.). 
 
5.3 NSEP distribution and collection statistics 
In 2000, 1,004,679 needles and syringes were sold or exchanged for used ones in New 
Zealand (NENZ, 2001).  The proportion of used needles and syringes returned for 
destruction improved from 26% of national sales in 1994 to 52.9% of sales in 2000 (NENZ 
website, 2002).   
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6. Effectiveness - Is the NSEP achieving its stated objective(s)? 
The prime objective of New Zealand’s NSEP is to reduce HIV transmission between 
people who inject drugs, and hence reduce the rate of infection for the entire community.  
Thus the most obvious ways to assess whether the NSEP is effective are to examine trends 
in HIV diagnoses in IDUs over time, and to compare New Zealand’s HIV rates with those 
of countries with analogous programmes and epidemics.  As noted by the first reviewers of 
New Zealand’s NSEP (Lungley and Baker, 1990), Australia provides a comparable model 
for infection trends, and this review will use Australian data for most of its comparisons. 
Secondary or implied measures of effectiveness also exist.  For example, the sharing of 
needles and syringes is strongly associated with the transmission of HIV and other blood-
borne viruses (Crofts et al, 1997); if this behaviour became less prevalent as the NSEP 
continued to operate, that would imply that needle and syringe provision and educative 
measures were influencing IDUs to reduce sharing frequency, thereby reducing 
transmission.  If research could demonstrate that IDUs who use the NSEP were less likely 
to have or acquire HIV, that would also support the case for effectiveness. 
 
6.1. Studies of Needle and Syringe Programmes’ Effectiveness 
This section (6.1) consists entirely of a lightly edited version of a portion of an article by 
Stephanie Strathdee and David Vlahov entitled “The Effectiveness of Needle Exchange 
Programs: A Review of the Science and Policy” (Strathdee and Vlahov, 2001). 
Numerous authors have reported associations between needle and syringe programmes 
(NSPs) and positive health outcomes for IDUs.  In 1988, Buning et al (1986) reported 
declines in needle sharing and injection frequency associated with NSP participation 
among IDUs in Amsterdam.  Other studies have since reported reductions in incidence of 
HIV, HBV and HCV infections (Normand et al, 1995; Van Ameijden and Coutinho 1988; 
Lurie et al, 1993; Hagan et al, 1995; Vlahov et al, 1997; Drucker et al, 1988), decreased 
needle sharing among HIV-negative and HIV-positive persons (Vlahov et al, 1997; 
Bluthenthal et al, 2000; Vertefeuille et al, 2000) decreases in syringe re-use, (Stimson, 
1995) and increased rates of entry into drug treatment programs (Heimer 1998; Brooner et 
al, 1998; Strathdee et al, 1999) in NSP attendees. 
In the United Kingdom and Australia, where NSPs were introduced early as part of 
comprehensive prevention programs, HIV epidemics among IDU have been essentially 
averted (Des Jarlais et al,. 1995; Stimson, 1995; Stimson, 1996).  An international 
comparison showed that in 29 cities with established NSPs, HIV prevalence decreased on 
average by 5.8% per year, but increased on average by 5.9% per year in 51 cities without 
NSP (Hurley et al, 1997).  In New York, NSPs have been associated with a dramatic 
decline in HIV incidence among IDUs (Des Jarlais et al, 2000). 
Although the overwhelming majority of studies have found NSPs to be associated with 
beneficial health outcomes, some studies have been equivocal in their findings.  Strathdee 
et al (1997) described an outbreak of HIV infection among IDUs that occurred within the 
context of a large, high volume NSP that had been introduced early.  More recently, Hagan 
et al (1999) reported no benefit of NSP attendance upon incidence rates of HBV and HCV 
among IDUs in Seattle, Washington.  A study in Montreal found HIV incidence was higher 
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among NSP attendees than non-attenders (Bruneau et al, 1997).  These findings have 
generated controversy surrounding the evidence of NSP effectiveness (Moss, 2000; 
Coutinho, 2000; Lurie, 1997).   
In the scientific community, discussion has centred on possible explanations for higher 
observed incidence of HIV among NSP attenders relative to non-attenders in some settings 
(Coutinho 2000; Lurie 1997; Schechter et al, 1999).  The most obvious explanation is 
selection bias; NSPs are likely to attract high-risk IDUs - people who engage in riskier 
behaviours than IDUs who mostly obtain syringes from other sources (Schechter, 1999; 
Gibson et al, 2001; Bastos et al, 1997).  In fact, Vancouver researchers demonstrated that 
selection bias could have entirely accounted for the higher HIV incidence rates observed 
among frequent versus infrequent NSP attenders (Schechter et al, 1999).  In San Francisco, 
IDUs who later began attending NSP had higher HIV incidence rates than those who never 
attended (Hahn et al, 1997).  It has also been noted that discrepant findings usually occur in 
settings where IDUs are legally able to purchase syringes in pharmacies (Schechter et al, 
1999; Bastos and Strathdee 2000; Vlahov and Junge, 1998).  This would heighten 
differences in risks between NSP attenders and non-attenders, since IDUs who can afford 
to buy syringes at pharmacies are likely to be relatively socioeconomically secure and 
therefore also at lower HIV risk.  Extended follow-up of the Montreal cohort has revealed 
no significant differences in HIV incidence between attenders and non-attenders of NSPs 
(Bastos and Strathdee 2000), which suggests that selection factors do indeed explain their 
earlier findings.    
There is no published evidence that NSPs can cause negative societal effects such as 
increases in drug use (Vlahov et al, 1997) or crime (Marx et al, 2000), or the formation of 
high-risk needle-sharing networks (Schechter et al. 2000; Valente et al, 1998).  Doherty et 
al (2000) demonstrated a significant decrease in the number of discarded needles on 
Baltimore’s street following the introduction of a NSP.  It is reasonable to state that there is 
now widespread agreement among scientists that NSPs do not cause social harms. 
 
6.2 HIV in New Zealand IDUs 
In this section the effectiveness of New Zealand’s NSEP is assessed in several ways, but 
principally by comparing figures on HIV in New Zealand IDU with those for other 
countries, and making projections of HIV diagnoses in IDUs with and without the 
introduction of the NSEP. 
 
6.2.1 HIV prevalence in New Zealand IDUs – international comparisons 
In 1990, 759 syringes were randomly selected from NE returns and subjected to HIV 
testing; only two (0.26%) had evidence of HIV contamination (Baker et al, 1992).  Testing 
saliva samples from 591 IDUs in 1992 yielded only 3 HIV-positives (0.51%) (Dickson et 
al, 1994).  A cross sectional survey involving 279 IDU carried out through needle 
exchanges in Auckland, Wellington, Christchurch and Dunedin over one week in 
December 1997 (Kemp and MacDonald, 1999) found that just two (0.9%) were HIV 
positive.  Thus (neglecting error bounds on these estimates, which are not available for the 
international figures used in coming comparisons in any case) HIV prevalence in New 
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Zealand IDUs is probably less than one per cent.  It seems sensible to rely on the most 
recent estimate, 0.9%. 
 
Table 6.1  Selected national HIV prevalences in injecting drug users (UNAIDS, 2000), in 
ascending order. 
 
Country Year Prevalence (%) 
Japan 1996 0.0 
Russian Federation 1996 0.4 
Iran 1998 0.8 
New Zealand 1997 0.9 
United Kingdom 1998 1.0 
Mexico 1997 1.1 
Australia 1996 1.7 
Switzerland 1999 1.7 
France 1990 3.0 
Egypt 1994 3.8 
Netherlands 1996 5.1 
Sweden 1995 5.3 
Ireland 1998 8.3 
Canada 1998 4.6-14.2 
Malaysia 1996 10.3-16.8 
Brazil 1998 28.0 
Peru 1990 28.1 
Italy 1993 23.0-33.6 
Thailand 1997 33.1-41.3 
Spain 1998 39.3-48.3 
 
New Zealand has the fourth-lowest HIV prevalence in IDUs of the countries listed in table 
6.1, and the lowest among more the developed countries in which studies have actually 
detected any HIV infections.  New Zealand’s IDUs enjoy lower HIV prevalence than those 
in countries that have employed similar approaches to the HIV epidemic, such as Australia 
and the Netherlands. 
 
6.2.2 HIV notifications in New Zealand IDUs – comparison with Australia 
To the 31st of December 2001, 47 HIV infections for which the principal exposure 
category was injecting drug use had been notified to New Zealand’s HIV/AIDS 
surveillance system (Eberhart-Phillips, 2002).  The total number of HIV/AIDS cases 
reported was 1558, meaning 3.0% of all New Zealand’s notifications were in injecting 
drug users (ibid).  As a fraction of the estimated number of IDU in New Zealand in 2001 
(23,760), HIV-infected IDU (assuming they were all alive and still injecting) would 
constitute 0.20%. 
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In Australia, 20,953 HIV/AIDS infections had been notified to the end of 2000, of which 
953 were in injecting drug users (National Centre in HIV Epidemiology and Clinical 
Research, 2001 – numbers estimated from percentage data), or 4.5% of all notified 
Australian HIV/AIDS cases.  As a percentage of the estimated number of IDU in Australia 
in 2001 (340,122), following the same assumptions as above, HIV-infected IDU would 
constitute 0.28%. 
Fewer of New Zealand’s IDUs appear to be diagnosed with HIV, and IDU as an exposure 
category represents a smaller fraction of overall diagnoses in New Zealand than in 
Australia.  Are these results potentially biased by proportionately higher rates of diagnosis 
in men who have sex with men (MSM) in New Zealand?  In Australia, by 2000 16,324 
MSM had been diagnosed with HIV, approximately 0.08% of the Australian population.  
In New Zealand, 816 people with the exposure category “homosexual contact” had been 
diagnosed with HIV, or approximately 0.02% of the total population.  Thus (allowing for 
the crudity of this comparison) it appears as though HIV notification rates really are lower 
among New Zealand than Australian IDUs. 
 
6.2.3 Projected HIV infections in New Zealand IDUs 
As described in the Methods section, New Zealand HIV infection data and IDU population 
estimates were used to adjust Australian data to estimate the number of HIV infections that 
would have occurred in IDUs in New Zealand if the NSEP had not been introduced, and to 
make projections of infections occurring with the NSP in place.  The annual differences 
between the two projections are the estimated numbers of extra HIV cases and deaths per 
annum that would have occurred in New Zealand if the NSEP had not been introduced in 
1988.  However, given the marked differences between Australia’s and New Zealand’s 
IDU scenes (described in the Methods section) which plausibly make HIV transmission 
less rapid in the latter, it was decided to treat those raw differences as upper bounds on the 
NSEP’s prevention effect, with the “mid-range” and lower-bound projections calculated by 
ratios derived from the HCV projection adjustment process (see section 4.4.2).  Figure 6.1 
shows the annual numbers of HIV cases avoided due to NSEP introduction with upper and 
lower bounds (raw data in table 1, Appendix 5; table 2 contains estimates of numbers by 
disease stage). 
On these estimates, by the end of 2001, New Zealand would have had 1,031 extra people 
living with HIV/AIDS had the NSEP not been introduced (range 268 - 1,793).  An 
estimated 20 more people (range 5 – 35) would have died due to HIV infections.  
Therefore, on the basis of our projections, New Zealand’s NSEP has been and remains 
effective in preventing HIV infections among IDUs. 
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Figure 6.1  Estimated numbers of HIV cases avoided per annum in IDUs as a result of 
NSEP introduction in New Zealand, 1981-2001 
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6.3 Hepatitis C in New Zealand IDUs 
The hepatitis C virus (HCV) was measured for the first time among New Zealand IDUs (in 
prison) in late 1991 (Brunton, 1995), thus was not a target for the NSEP when initially 
established in 1988.  Nevertheless, with HIV remaining well under control, the principal 
viral threat to New Zealand IDUs’ health is the hepatitis C virus. 
 
6.3.1 HCV prevalence in New Zealand’s IDUs – international comparisons 
HCV is thoroughly entrenched in New Zealand’s IDU population, just as in Australia and 
other western countries.  Five studies of HCV seroprevalence in IDUs in drug treatment 
programmes have been carried out in New Zealand.  Woodfield et al’s (1994) study of 110 
Auckland IDUs returned a seroprevalence of 73%; Robinson et al’s (1995) study of 92 
IDUs in Wellington found a rate of 77%; among 116 IDUs in Christchurch, Chetwynd et al 
(1995) measured a prevalence of 84.1%; in Taranaki, 72% of 88 IDUs were found to have 
been exposed (Judson, 1999); and Carter et al (2001) surveyed 195 Wellington IDUs, 
84.2% of whom were HCV-antibody-positive.  In a national study that recruited 241 
injecting drug users from both treatment and community settings, a rate of 64.3% was 
detected (Kemp et al, 1998).  A cross-sectional survey involving 279 IDUs carried out 
through needle exchanges in Auckland, Wellington, Christchurch and Dunedin over one 
week in December 1997 found that 53% (95% CI, 47-60%) were anti-HCV positive 
(Kemp and MacDonald, 1999).   
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Hepatitis C prevalences found in IDUs in other countries vary enormously, frequently 
depending on methods of recruitment (eg. through social networks, drug treatment centres, 
or NSPs) and nature of the target sample (eg. adults, recent initiates, prisoners); however, it 
is reasonable to state that in all countries in which injecting drug use has been occurring for 
two decades or more, the minimum hepatitis C prevalence measured among adult IDUs is 
about 50%, and most studies report higher figures.  Hocking et al (2001) calculated a 
weighted mean HCV seroprevalence measured in 160 studies involving 46,419 IDUs from 
34 countries of 70.2%.  Regional mean prevalences were 77.2% in all Asian studies, 67.3% 
in Europe, 84.2% in North America, 73.3% in South America studies, and 59.1% in 
Australasia (ibid).  New Zealand’s most recent seroprevalence measurement of 53% 
(Kemp and MacDonald, 1999) is therefore towards the lower end of the global range. 
In Australia, annual national NSP surveys between 1995 and 2001 have returned HCV 
antibody prevalences (adjusted for state population size biases) of 63%, 54%, 51%, 49%, 
53%, 53%, and 58% (NCHECR, 2001; NCHECR, 2002).  The 1997 figure was statistically 
inseparable from that measured in New Zealand by Kemp and MacDonald (1997) using 
identical methods; and the crude mean of the seven survey prevalences is 54.4%.  It seems 
clear that the HCV epidemics among Australian and New Zealand IDUs are at similar 
stages. 
Several reasons have been postulated for the high prevalence of hepatitis C in IDUs in 
New Zealand and elsewhere, despite clear evidence of risk behaviour reduction and very 
low prevalences of HIV.  HCV is much more infectious than HIV, with the probability of 
infection following a needlestick injury from an infected person being 3-10%, against an 
estimated 0.3% for HIV (Crofts et al, 1999a).  A greater-than-50% background prevalence 
of HCV in IDUs means that any time two or more IDUs inject together, the chances are 
excellent that at least one will be carrying the virus (ibid).  HCV infection among 
Australian (and presumably, New Zealand) IDUs predated the introduction of needle and 
syringe exchange programmes by at least 15 years, whereas the arrival of HIV in our IDU 
populations was probably nearly concurrent (Crofts et al, 1999b).  Finally, even though 
IDUs’ main HCV risk behaviour – sharing needles and syringes - appears to have been 
greatly reduced in both prevalence and frequency, it has been shown that many items of 
other injecting equipment can be contaminated with blood and (theoretically) transmit 
HCV.  Several authors have now produced convincing support for the probability that 
transmission of HCV can occur in the absence of needle-sharing (Thorpe et al, 2002; 
Crofts et al, 2000). 
 
6.3.2 HCV notifications in New Zealand IDUs 
Unlike in the case of HIV, HCV diagnoses and notifications are a very poor reflection of 
the true prevalence or status of the epidemic in a population.  HCV infections are 
frequently asymptomatic, and many people who have the virus do not discover it for years 
or even decades; therefore many diagnoses are “old” infections rather than recently 
acquired ones.  Thus there is little mileage in comparing diagnoses (via notifications) 
across the two countries. 
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6.3.3 Projected HCV infections in New Zealand IDUs 
As described in the Methods section, New Zealand IDU population estimates are used to 
adjust Australian data to estimate the number of HCV infections that would have occurred 
in IDUs in New Zealand to 2001 if the NSEP had not been introduced and with the NSEP 
in place.  The differences between those projections are the estimated numbers of extra 
New Zealanders who would have been living with HCV if the NSEP had not been 
introduced, and are shown in figure 6.2 below.  (Data used to produce figure 6.2 are shown 
in table 3, Appendix 5; table 4 shows numbers prevented by disease stage).   
On these estimates, by the end of 2001, New Zealand would have had 1,454 extra people 
living with hepatitis C had the NSEP not been introduced (range 378 – 2,531) (but note 
that only an estimated 673 [range 175 – 1,171] of those would be diagnosed and therefore 
treated).  On the basis of these projections, New Zealand’s NSEP has been effective in 
preventing HCV infections among IDUs. 
 
Figure 6.2  Estimated numbers of HCV cases avoided per annum in IDUs as a result of 
NSEP introduction in New Zealand, 1981-2001. 
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6.4 Rates of needle and syringe sharing 
The fundamental reason for the existence of NSEPs is to give IDUs the means to inject 
with a new needle and syringe every time and therefore reduce transmission of blood-
borne viruses between them and to other members of the community.  NEs (in New 
Zealand) are also required to provide their clients with information about safer drug use, 
while pharmacy outlets provide generic health education and safer sex material.  
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Consequently, reported rates of sharing of needle and syringes can be used as an indicator 
of NSEP effectiveness in educating IDUs and providing them with clean equipment.  Table 
6.2 below shows rates of needle sharing recorded in surveys of New Zealand IDU, 
including that conducted as part of this Review. 
 
Table 6.2  Prevalences of needle-sharing reported among New Zealand IDU, 1987-1999. 
 
 Study Year % used someone else’s needle in last: 
  of survey 12 months 3 months month 
 Robinson et al, 1987 1985 92 
 Robinson et al, 1987 1986 78 
 Lungley et al, 1988 1987/88  57 
 Lungley and Baker, 1990 1988/89  41 
 Robinson et al, 1995 1992-4  33 
 Robinson et al, 1995 1992-4 43 
 Kemp et al, 1998 1994   50 
 Kemp and MacDonald, 1999 1997   19 
 NZ NSEP Review, 2002 2002   6 
 
Although there are few data points to go on, these data certainly suggest that a gradual but 
sustained decline has occurred in the prevalence of needle-sharing among New Zealand 
IDUs since the mid-80s.  In particular, the three most recent figures show a very 
substantial reduction in prevalence of sharing (past month), from 50 to six per cent over 
eight years.  It is impossible to definitively associate this decline with the activities of New 
Zealand’s NSEP, but as the programme is the primary means by which IDUs are educated 
about ways to reduce harm associated with injecting, it is reasonable to conclude that the 
NSEP has been effective in reducing needle-sharing among IDU. 
While a very low 6% of Review survey respondents reported sharing a needle and syringe 
in the previous month, it should be noted that (perceived) inadequate service delivery on 
the part of some respondents means that this behaviour is certain to continue.  One hundred 
and fifteen (37.7%) of 305 respondents reported difficulty in obtaining clean injecting 
equipment when required.  Eighty-four of those 115 (73.0%) agreed that as a result they 
shared equipment or used someone else’s equipment more often than they otherwise 
would.  The most frequently-cited reason why IDUs reported difficulty in obtaining needle 
and syringes was limited hours of operation (see section 9.1 for details). 
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6.5 NSEP coverage 
6.5.1 Meeting demand 
In the NE users’ survey conducted for this Review, 115 of 305 (37.7%) of respondents 
reported difficulty in obtaining clean injecting equipment when required.  One hundred and 
seven people provided a response to question 7a, which asked how often obtaining clean 
injecting equipment had been difficult in the previous month; only one responded 
“always”, four “most of the time”, and nine “half the time”.  Thus, of all 316 respondents, 
only 14 (4.4%) frequently had difficulty in obtaining clean injecting equipment in the 
month prior to the survey.   
It must be remembered that this survey was of NE users only, so neglected or under-
sampled people who are (respectively) unable to or infrequently visit NEs.  Nevertheless, 
the conclusion must be that the overwhelming majority of people who visit NEs are happy 
with their access to clean needles and syringes.  
 
6.5.2 Geography 
As noted in the section above, 115 of 305 (37.7%) of respondents reported difficulty in 
obtaining clean injecting equipment when required; of those 115, 27 (23.5%, or 8.9% of all 
people who responded to this question) said this was because they lived a long way from 
an outlet.  Taken at face value, the survey suggests that the geographical coverage of the 
NSEP is excellent, with better than 90% of respondents perceiving little or no difficulty 
with access due to distance from an outlet.  Of course, this is undoubtedly an overestimate 
– as described in section 4.4.3, the survey is certain to have under-sampled IDUs who have 
difficulty with access to the NSEP because it was conducted at the very locations being 
asked about.   
In consultations, several NE staff said they were aware of many IDUs living an hour or 
more away by car who couldn’t get to the NE regularly or often (due largely to transport 
costs) and were frequent re-users of injecting equipment.  One staff member described 
receiving returned syringes with the lettering worn off their barrels and plungers wrapped 
in tape because the seals have perished from repeated boiling.   
Several geographical regions were singled out for particular mention as being under-
serviced by needle exchange.  Wanganui, the Kapiti coast, Masterton, Hastings, Southland 
and the west coast of the South Island were mentioned as regions with significant injecting 
populations but no peer-based needle exchange.  Invercargill is 200 km from Dunedin, has 
half as many residents and a similar proportion of IDUs (based on methadone provision), 
but has no NE.  An informal survey of users revealed that the average frequency of reuse 
of needles and syringes in Invercargill is 6-7, against only 1-2 in Dunedin (Hilary 
Lawrence, pers comm.).  Perhaps the most glaring gap in coverage is, paradoxically, in 
New Zealand’s largest city.  Auckland has only one NE (ADIO Trust), but on a per-capita 
basis, compared to any other urban region in New Zealand, it should have four.  Its 
congested transport system and very low population density exacerbate the difficulty faced 
by many users in reaching the NE, particularly those from west and south Auckland.  (On 
the other hand, it was also suggested that Aucklanders were less concerned about 
potentially risking their anonymity by using pharmacy-based exchange because of the 
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number of pharmacies available to them.  Auckland’s pharmacies provide a much larger 
fraction of overall distribution than those in other major New Zealand cities, although 
whether this is due to necessity rather than choice is impossible to say.) 
 
Recommendations: That consideration be given to opening a second peer-based NE in 
Auckland, to bring per-capita service coverage closer to the level 
which exists elsewhere in New Zealand. 
That consideration be given to improving NSEP coverage on the 
South Island’s west coast and Southland by opening branch NEs 
and/or upgrading and expanding existing pharmacy outlets. 
That consideration be given to increasing the reach of the NSEP by 
enabling and/or encouraging the provision of needle exchange 
services through existing health service infrastructure, such as 
Community Health Centres and Sexual Health clinics. 
 
6.5.3 Ethnicity 
In studies of New Zealand IDUs that included ethnicity data, (Chetwynd et al 1995, Kemp 
et al, 1998, Lim et al, 1999 and Judson, 1999) Maori were the largest proportion (6.8%, 
9%, 12% and 11% respectively) after European.  Twelve-and-a-half per cent of the NE 
users surveyed for this Review described themselves as having at least part-Maori 
ancestry.  Whether any of these figures accurately represents the proportion of Maori 
amongst injecting drug users in New Zealand is unknown.   
In consultations, North Island NE managers and staff opined that fewer Maori used their 
services than might be expected on a population basis.  One reason advanced for this were 
that Maori are economically disadvantaged relative to the rest of New Zealand’s 
population, so are less likely to purchase new equipment and less likely to have access to 
transport to visit NEs.  Another proffered reason for (perceived) lower-than-expected 
Maori participation in the NSEP was cultural factors, notably familial disapproval – Maori 
are less likely to use NEs and pharmacies in case they are seen and their families find out.  
Of course, it is also entirely possible that fewer Maori inject drugs than do people of other 
ethnic backgrounds, but evidence is lacking.  
The issue of culturally inappropriate approaches to blood associated with NE use is another 
factor potentially restricting Maori attendance.  In traditional Maori belief systems, body 
fluids, and blood in particular, are regarded as tapu (sacred or special).  These special 
wastes must be appropriately disposed of by burial in the earth (all sewage pre-European 
settlement went into pit latrines).  This also means that burning blood (when syringes are 
destroyed) and keeping blood-stained materials (such as used syringes or disposal 
containers) in areas where food is prepared or served is culturally inappropriate..  The 
manager of NINE, Gerry MacPhail, has consulted Maori kaumatua in his region about 
what NE users should do with their bloodied fits, and received advice that they should 
wash them out with seawater, bury the seawater, then return the fits to the exchange.  This 
sort of information, if widely communicated might improve the cultural safety of NEs.  
However, how much this would help to bring more Maori into NEs is still an open 
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question.  Cost and fear of being identified as an IDU may be stronger influences on the 
behaviour of Maori IDI who are dislocated from their culture.  
Consultations with NE managers and staff revealed some concern that other ethnic groups, 
South-East Asians in particular, were not being reached in proportion to their presence in 
New Zealand’s IDU population.  The Review’s survey included only 5 individuals (1.7%) 
of Asian ethnicity.  Pacific Islanders were mentioned by several consulted people as 
another group that is currently thought to be under-represented among NSEP users. 
 
6.6 Collection effectiveness 
The proportion of used needles and syringes returned for destruction improved from 26% 
of national sales in 1994 to 52.9% of sales in 2000 (NENZ website, 2002).  Nevertheless, 
this is a surprisingly low return rate given the financial benefits to IDUs of returning their 
used equipment (in the form of discounts on new equipment), and given that in Australia, 
where distribution and collection are completely separated, the rate of returns is almost 
identical.   
Several explanations for the low return rate may exist.  The size of the syringes typically 
used by New Zealand IDUs (3 and 5mls) means they are difficult to conceal relative to the 
1ml used in Australia, so fear of social stigma and police attention comes into play.  New 
Zealand’s relatively dispersed population may also be a factor, making it less attractive for 
people to transport used equipment. 
In the Review survey, respondents were asked if they did not return all their used needles 
and syringes for destruction, why not?  One hundred and sixty-four of the 316 respondents 
(51.9%) did not answer the question, presumably signifying that they did return all their 
used fits – in which case the calculated figure is nearly identical to the national return rate.  
In order of frequency, responses given were: 
• it’s a hassle – 53 responses 
• fear of arrest - 51 
• prefer to burn or otherwise discard myself - 22 
• child safety - 13 
The first response probably reflects the point mentioned earlier about the sheer bulk of the 
injecting equipment typically used in New Zealand, and is equally probably correlated with 
the second-most-frequent response, because a bulky load of syringes is difficult to conceal 
from view. 
 
6.7 Consultation outcomes - effectiveness 
All consultation participants were asked if they could specify any ways in which the NSEP 
might improve the effectiveness of its operations without necessarily consuming extra 
resources.  This is obviously a very difficult question to answer, and few meaningful 
responses were received.   
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NE staff and other people closely associated with NEs were unanimous in saying that one-
for-one (new for old) exchange would improve their ability to fight hepatitis C and 
improve syringe collection rates, but equally were unanimous in recognising that 
implementation of one-for-one would require extra funding. 
Representatives of New Zealand’s Police Services said they had very little to do with the 
NSEP and very few complaints, so assumed it must be working smoothly. 
Euan Galloway (Pharmaceutical Society) suggested that ongoing training on needle 
exchange issues for pharmacists and pharmacy staff on would increase their effectiveness. 
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7. Efficiency - Is the NSEP achieving its objectives cost-effectively? 
 
The efficiency of an NSEP can be gauged by calculating its cost-effectiveness in terms of 
cost of infections avoided per dollar invested in the NSEP, or by comparing its 
performance with other programmes. 
 
7.1. Studies of Needle and Syringe Programme efficiency 
Holtgrave et al (1998) estimated that a national policy of funding NEs, pharmacy sales and 
syringe disposal in the United States would cost $34,278 U.S. per HIV infection prevented, 
well below the lifetime costs of treating a single HIV infection.  (The same authors also 
found that in settings where HIV incidence is low - below 2% per annum - the cost-
effectiveness of sterile syringe provision through pharmacy sales exceeds that of NEs.  If 
Holtgrave et al’s finding holds true for New Zealand, this country’s relatively dispersed 
population makes it even more important that the maximum possible number of 
pharmacies is involved in the NSEP, as well as other types of outlets.) 
Several studies have compared BBV incidence or prevalence in NSP attendees and non- 
attendees (Bruneau et al, 1997; Des Jarlais et al, 1995; Hagan et al, 1999; van Ameijden et 
al, 1994).  Hurley et al (1997) compared NSP implementation in countries with sustained 
low HIV prevalence to those with high HIV prevalence, and compared changes in HIV 
prevalence in cities with and without NSPs.  The data generally show NSPs to be effective 
in preventing HIV transmission. 
Health Outcomes International (2002) compared rates of change of HIV seroprevalence in 
cities that never introduced NSPs with cities that did introduce NSPs.  Cities that 
introduced NSPs had a mean annual 18.6% decrease in HIV seroprevalence, compared 
with a mean annual 8.1% increase in HIV seroprevalence in cities that had never 
introduced NSPs (the difference being only weakly statistically significant, p=0.06).  In 
cities with an initial HIV prevalence below 10% at least three years of sero-survey data, the 
mean annual decrease in HIV prevalence was 4.0% in cities that introduced NSPs, 
compared with a mean annual 28.6% increase in cities without NSPs (difference not 
statistically significant). 
 
7.2 Cost/benefit analysis for New Zealand’s NSEP 
As described in detail in the methods section, the numbers of people living with HIV or 
HCV prevented by NSEP introduction can be multiplied by annual treatment costs to 
produce gross annual cost/benefit figures.  Subtracting the annual investment in the NSEP 
gives an annual net return on investment, which can then be added to produce cumulative 
costs or benefits for a given period. 
 
7.2.1 Public expenditure on the NSEP 
Unfortunately the New Zealand Ministry of Health was unable to supply expenditure data 
relating to the NSEP prior to 2000.  To model annual expenditures since 1988, it is 
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assumed that each year’s expenditure was 95% of its successor – ie, that if the NSEP cost 
$1,380,206 in 2001 (according to Ministry of Health figures) it cost $1,311,195 in 2000.  
(Note that the Ministry of Health did supply an NSEP expenditure estimate for 2000 – 
$903,276 – but as it is considerably smaller than the 2001 figure, modelling earlier 
expenditures by simply drawing a line backwards through the 2001 and 200 figures gave 
unrealistically low results.  Nevertheless, the 2000 expenditure figure is used to estimate 
needle and syringe distribution costs in section 7.3.)  This procedure results in an 
expenditure estimate (unadjusted for inflation) for the first year of the NSEP of $708,508, 
and a total expenditure to end 2001 of $10,644,588, both of which are likely to be 
conservatively high.  Annual and cumulative expenditure estimates are presented in table 
5, Appendix 5. 
Note that figures for expenditure on injecting equipment by NSEP consumers, included in 
total Australian NSP expenditure by Health Outcomes International et al (2002), were 
unavailable for New Zealand. 
 
7.2.2 Costs of treating HIV 
Annual costs of treating people living with HIV infection were reconstructed from Health 
Outcome International et al’s (2002) ROI data and converted to New Zealand dollars.  
Amounts range from $1,164 per annum for early-stage HIV disease in the early 1980s to 
$88,310 per annum for AIDS between 1990 and 1996.  Costs of treating AIDS have since 
shrunk, while the costs of treating early-stage IV have increased approximately eight-fold 
due to the advent of anti-retroviral therapy in the mid-1990s.  The full dataset is in 
Appendix 5, table 6. 
 
7.2.3 Costs of treating HCV 
Annual costs of treating people living with (diagnosed) HCV were reconstructed from 
Health Outcome International et al’s (2002) ROI data.  Amounts range from $244 per 
annum for an early-stage chronic hepatitis C infection in the late 1980s to $456 per annum 
for cirrhosis, $120,924 per episode of hepatocellular carcinoma and $200,531 per episode 
of liver failure (see Appendix 5, table 7). 
 
7.2.3 Value of HIV and HCV cases avoided, 1988-2001 
It is estimated that New Zealand would have had 1,031 extra people (range 268 – 1,793) 
living with HIV/AIDS by the end of 2001 had the NSEP not been introduced (details in 
section 6.2.3).  Treatment costs for these people (and those who died) would have added an 
estimated $34,363,706 (range $8,934,564 - $59,792,849) to New Zealand’s total healthcare 
outlay between 1988 and 2001.   
New Zealand’s extra healthcare costs between 1988 and 2001 due to treating the 673 
(range 175 – 1,171) extra diagnosed HCV infections that would have resulted from the 
non-introduction of the NSEP are estimated at $1,314,810 (range $341,851 - $2,287,769). 
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Combining the savings from HIV and HCV infections prevented ($35,678,516), and 
subtracting estimated total expenditure on the NSEP between 1988 and 2001 of 
$10,644,588, gives a net benefit due to the NSEP of $25,033,928 (range -$1,368,174 - 
$51,436,030) for the period 1988-2001.  Put another way, every $1 spent on the NSEP has 
saved an estimated $3.35 (range $0.87 - $5.83) in healthcare costs avoided over the period 
of investment. 
Annual return on investment in the NSEP (counting only the costs that were estimated to 
have been avoided between 1988 and 2001) was negative until 1995, when the estimated 
net benefit to the taxpayer was $15,129.  The programme’s estimated net benefit for 2001 
was $9,925,643.  In cumulative terms (again counting only the costs that were estimated to 
have been avoided between 1988 and 2001), the NSEP represented a net cost to the New 
Zealand taxpayer until 1997, when its total benefits first exceeded costs by an estimated 
$44,420.   
Figure 7.1 shows the cumulative cost/benefit accruing from the estimated cases of HIV and 
HCV avoided as a result of investment in the NSEP for 1988-2001 (data in table 8, 
Appendix 5).   
 
Figure 7.1  Cumulative cost/benefit of New Zealand's NSEP, 1988 - 2001. 
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7.2.4 Value of HIV and HCV cases avoided, 1988 until death 
When the costs of treatment for the extra New Zealanders infected with HIV between 1988 
and 2001 in the absence of the NSEP are projected forwards until all have died (by the year 
2070), their cumulative estimated value is $197,829,040 (range $51,435,550 - 
$334,222,530).   
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Estimated treatment costs until all extra New Zealanders infected with HCV due to non-
establishment of the NSEP have died (by 2076) total $15,090,234 (range $3,916,013 - 
$26,256,400). 
Combining the estimated avoided treatment costs for HIV/AIDS and HCV, minus 
estimated total expenditure on the NSEP between 1988 and 2001 of $10,644,588, gives an 
estimated net benefit due to the NSEP of $202,274,686 (range $44,706,975 - 
$359,834,342).  Every $1 spent on the NSEP between 1988 and 2001 saves an estimated 
$20.00 (range $5.20 - $34.80) in lifetime healthcare costs avoided. 
 
7.3 Distribution efficiency 
In 2000, 1,004,679 needles and syringes were sold or exchanged for used ones in New 
Zealand (NENZ, 2001).  The entire NSEP cost $903,275.93 in 2000, meaning the average 
cost to the taxpayer of distributing a single needle and syringe to an IDU in New Zealand 
in 2000 was $0.90.   
In Australia, NZ$23,607,600 of public money (not including consumer expenditure, nor 
costs associated with retail pharmacies which sell needles and syringes on a commercial 
basis, for which reliable data are not available) was spent on the NSP in 1999-2000, and 
31,848,000 needles and syringes were distributed to IDUs, at a unit cost of NZ$0.74 
(Health Outcomes International et al, 2002). 
The difference between the Australian and New Zealand programmes’ unit costs is 
probably the result of economies of scale, demography and geography.  Australia’s NSP 
delivered over 30 times as many needles and syringes as New Zealand’s NSEP in 2000 to 
an IDU population estimated to be nearly 15 times as large.  New Zealand’s population is 
relatively dispersed compared to Australia’s, where around 65% of the population resides 
in the state and territory capital cities alone (Australian Bureau of Statistics, 1996).  About 
a third of New Zealand’s population lives in Auckland, but the bulk of the remainder of the 
population is spread across dozens of cities and towns with populations between 250,000 
and 10,000.  As the target group – IDUs – is a very small fraction of the overall population, 
service efficiency is greatly improved if the population is highly centralised in urban areas.  
New Zealand’s unique geography may also contribute to the NSEP’s relative inefficiency, 
the country being divided into two main islands and containing other significant natural 
barriers such as mountain ranges, lakes and rivers which further isolate communities, and 
mean that direct distances between urban centres are much less indicative of actual 
travelling time and efficiency than they would be in Australia.   
Rather than comparing New Zealand’s NSEP unit output cost with Australia’s as a whole, 
a better comparison might be with the unit cost for the Australian states.  Estimated unit 
cost per needle and syringe per state varied from NZ$0.33 in 1999/2000 in South Australia 
to NZ$1.34 in Western Australia (Health Outcomes International et al, 2002).  Unit costs 
in the two most populous states, New South Wales and Victoria, were NZ$1.07 and 
NZ$0.93 respectively, very similar to the New Zealand NSEP’s NZ$0.90. 
It could also be argued that it is a simpler matter to estimate total costs for New Zealand’s 
NSEP than to do so across all Australian programs.  Australian NSPs are integrated with 
other healthcare programs to varying extents, whereas in New Zealand the NSEP is 
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essentially a stand-alone entity.  Because it is more difficult to account for all costs for 
Australian NSPs, total expenditure figures are likely to be understated relative to New 
Zealand’s. 
 
7.4 Consultation outcomes - efficiency 
As was the case when asked about effectiveness, few NE staff or associated persons were 
able to pinpoint anything which might increase efficiency of NSEP output within the 
current resource level. 
Suggestions included improved networking and sharing of resources between NENZ and 
Australian and international needle exchange organizations, one-for-one (new for old) 
needle exchange, and training for pharmacy and NE staff. 
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8. Regulatory issues  
 
8.1 The Misuse of Drugs Act 
Needle exchange was legalised in New Zealand through the introduction of the Health 
(Needles and Syringes) Regulations 1987, which allowed the sale of needles and syringes 
to injecting drug users provided their sale is part of the NSEP.  The regulations (amended 
in 1998) also create a legal defence to the charge of possession of injection equipment, 
which (at the time of writing) remained an offence under the Misuse of Drugs Act [section 
13(1)(aa)].   
Under the Misuse of Drugs Act a person can be charged and prosecuted for possession of 
needles and syringes obtained under the Needle and Syringe Exchange Programme but has 
a defence under the Health (Needles and Syringes) Regulations.  Nevertheless, police are 
empowered to detain a person and bring him or her to trial for the offence, and this process 
itself constitutes a penalty.  In 2000, more than 100 people were successfully prosecuted 
for possession of instruments legally obtained under the scheme (Needle Exchange 
Services Trust, 2002).  This occurs because drug users charged with possession of injection 
equipment simply plead guilty rather than defending the charge since this improves their 
chances of immediate release.  The possession of needles and syringes charge is also 
sometimes used as a holding charge while searches are conducted and further 
investigations made (ibid).   
The threat of arrest and prosecution under the Misuse of Drugs Act [section 13(1)(aa)] has 
made IDUs reluctant to risk being caught carrying injection equipment, particularly if it 
has been used.  IDUs are in effect being deterred from disposing of their used injecting 
equipment in the safest possible way – by returning it to an exchange or pharmacy – and 
from acquiring clean equipment to help them reduce risks of BBV infection.  The NSEP is 
funded to reduce re-use and sharing of needles and maximise return of used injecting 
equipment for the benefit of public health and safety, yet simultaneously police are 
arresting IDUs for carrying such equipment; this means public funds are being wasted and 
public health is at risk.  The legislation also makes little sense from a police occupational 
health and safety perspective; if IDUs have an incentive to deny possession of injecting 
equipment (ie, to avoid arrest), police may be at risk of a potentially infectious needlestick 
injury during a body search.  During the consultation with police for this Review, it was 
clear that needlestick injuries are their single greatest point of interest in the entire field of 
injecting drug use.  Several police spokesmen expressed approval for the concept of 
carriage of clean injecting equipment being unequivocally licit.  They described the 
situation which existed before the current Act came into force, in which police conducting 
a house search would not be told if needles and syringes were present and were therefore at 
risk of needlestick injuries, with the present situation in which people could warn police 
about their injecting equipment without (in theory) fear of prosecution for possession of an 
illegal article. 
The Ministry of Health is also of the view that this anomaly needs to be withdrawn.  In the 
Ministry of Health consultation for this Review, it was clear that the Ministry is well aware 
of the way the Act works against public health principles.  In early 2002, the Ministry 
succeeded in getting New Zealand’s inter-agency committee on drugs to agree to submit an 
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amendment to the Act to Parliament, which will have the effect of making it no longer an 
offence to possess legally-obtained needles and syringes (Brendon Baker, Ministry of 
Health, pers comm.).  Its passage is obviously dependent upon New Zealand’s political 
processes (including an election due sometime in 2002) but as to date the NSEP has been 
strikingly non-controversial, one imagines the amendment will eventually pass.  The result 
should be mutually beneficial to the NSEP, the police and public health. 
 
Recommendations: That New Zealand’s parliament approve the proposed amendment to 
the Misuse of Drugs Act which would remove the offence of 
possession of needles and syringes legally obtained through the NSEP. 
That basic training for NZ police include a short session on New 
Zealand’s harm minimisation policy and the NSEP.  NENZ should 
liaise with police to achieve this goal. 
 
8.2 One for one (new for old) needle and syringe exchange 
Free ‘one-for-one’ is universally seen as the holy grail for needle and syringe exchange in 
New Zealand by the NEs, both in terms of provision and disposal.  This view is based on 
the experiences of NEs which have attempted or continue to offer one-for-one exchange.  
Distribution increases, both as a result of the exchange’s hinterland expanding and 
frequency of re-use dropping, and return rates rise towards and even over 100% (due to 
IDUs returning syringes bought or obtained elsewhere).  Drugs Project (Wellington), and 
the Palmerston North and Napier NEs have been offering one-for-one more or less 
continuously since 1995 (on 3ml syringes and choice of needle), and achieve rates of 
return always close to and sometimes over 100%.  The experience at DIVO is salutary; a 
trial of one-for-one exchange began in mid-1999 with Ministry support, and was continued 
as long as possible using core NE funding, during which time return rates rose to 90%.  
The policy had to be abandoned in late 2001 due to its cost, and six months afterwards the 
return rate had dropped below 80% (Hilary Lawrence, DIVO, pers comm.).  A single year 
of running a one-for-one policy cost DIVO $13,000 (Hilary Lawrence, DIVO, pers comm.) 
- approximately 1½ times the annual cost of treating one early-stage HIV infection in 2001.  
The NE users’ survey provides some numerical evidence of the effectiveness of one-for-
one exchange as a problem limitation mechanism.  Mean frequency of needle and syringe 
re-use reported by IDUs who completed questionnaires at Drugs Project, Palmerston North 
and Napier (the NEs offering one-for-one at the time of the survey) was significantly lower 
than that for IDUs at other NEs (1.07 vs 1.70 times, p < 0.01).  Furthermore, mean 
frequency of reported needle and syringe sharing was lower among IDUs at the three NEs 
offering one-for-one (0.03 vs 0.13 times in the previous month, p < 0.05).  Syringe re-use 
promotes vein damage, abscesses and increases risk of cellulitis and other bacterial 
infections, and sharing a used needle is the primary risk factor for HIV and hepatitis C 
infection; if one-for-one decreases the frequency of these behaviours it must logically lead 
to reduced incidence of disease and lower overall healthcare costs. 
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The Ministry of Health’s own Hepatitis C prevention discussion document contains the 
statement “ideally we would provide a new for old policy but there is no new money being 
made available”. 
 
Recommendation: That the costs and benefits that would result from the introduction of 
free one-for-one (new for old) needle and syringe exchange in New 
Zealand be formally investigated. 
 
8.3 Sharps disposal bins in public areas 
Support for syringe disposal bins in public places was expressed by many of the people 
consulted, including Maree Jensen (Pharmacy Guild) and the New Zealand Police.  The 
value to the wider community of enabling safe needle disposal was widely recognised.  
Potential locations suggested included the standard ones of public toilets, as well as 24 
hour service stations.  Benefits for users include the preservation of anonymity and - as 
IDUs remain fearful of being arrested with used equipment – less chance of unwanted 
police attention.  They may also have to role to play if the apparent trend towards 
amphetamine injecting continues in New Zealand, because drug injecting may become 
more visible than has historically been the case with home-based opiate use.   
In a slightly different twist, Palmerston North council has reportedly installed a syringe 
disposal bin in their recycling centre (where people drop off cans, bottles, paper and other 
domestic recyclables), which seems an excellent idea.  This must also serve to reinforce the 
fact that syringes are not permitted in domestic rubbish and should be separated. 
 
8.4 The Action on Hepatitis C prevention discussion document  
The universal response received when people were asked for their views on the Action on 
Hepatitis C prevention discussion document this was that it is a good framework but 
essentially worthless unless backed up with resources.  Most people consulted were 
pleased that the Ministry of Health recognises that hepatitis C virus is primarily transmitted 
by IDU and has a sound understanding of all the associated issues, but were not confident 
that any action would result from the process. 
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9. Service Delivery Issues 
 
9.1 Meeting consumer’s needs 
In the Review’s survey of NE users, people who responded in the affirmative to the 
question “Do you ever find it hard to get fits when you want them?” were asked to provide 
reasons why.  Three of the responses related to service delivery issues; 
• “Exchange’s hours don’t always suit me” - 57 of 115 (49.6%) 
• “Nearest pharmacy’s hours don’t suit me” - 18 (15.7%) 
• “prices of injecting equipment are too high” - 5 (4.3%) 
NEs’ hours of operation were the most frequently-given reason given for difficulty in 
obtaining injecting equipment.  Hours of operation were also NE users’ sixth-most 
frequently-chosen of option for improving NE services (chosen by 23.1% of respondents).  
(It should be noted that the 57 respondents citing hours of operation as a problem are only 
18.7% of the 305 who reported difficulty in getting fits.) 
 
Recommendation: Consideration should be given to expanding the use of electronic 
dispensers at NEs to provide after-hours exchange services. 
 
9.2 NE users’ perceptions of NE service 
When asked to rate their local NE’s service on a five-point Likert scale (very poor, poor, 
middling, good, very good) 68 of 308 respondents (22.1%) selected “good” and 229 
(74.4%) “very good”, giving a combined “good or very good” response frequency of 
96.5%. 
Survey respondents were then asked “what would most improve the exchange’s service for 
you?”, and given a set of fifteen options from which to choose up to four.  The response 
frequencies are shown in table 9.1. 
 
Just over 55% of respondents selected “free one-for-one exchange” or “a lower price for 
fits” as one or two of their four preferred options for improving NE service, and over just 
over 47% chose “out-of-hours fit vending machines” or “longer opening hours”.  Clearly, 
NE users see the best ways to improve NE service as being increased availability of 
equipment in terms of economic and temporal access. 
Options for improving NE services which related to quality of service were chosen by very 
few survey respondents.  Only 14 (4.5%) selected “better staff attitudes”, 12 (3.9%) “more 
or better harm reduction info”, and 5 (1.6%) “better-trained staff”.  NE users appear to be 
very satisfied with the quality of the service they receive at NEs. 
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Table 9.1  NE users’ preferred methods of improving NE services. 
 Option Number selecting Percentage (of 308) 
 free one-for-one (new for used) exchange 132 42.9 
 out-of-hours fit vending machines 113 36.7 
 lower prices for fits 92 29.9 
 on-site hepatitis C and HIV testing  79 25.6 
 lower prices for other injecting equipment  76 24.7 
 longer opening hours  73 23.7 
 on-site hepatitis A & B vaccinations  58 18.8 
 on-site counselling services  45 14.6 
 a greater range of injecting equipment 27 8.8 
 more information about hepatitis C & HIV  21 6.8 
 more time for staff to advise & refer  21 6.8 
 more or better general healthcare info  19 6.2 
 better staff attitudes  14 4.5 
 more or better harm reduction info 12 3.9 
 better-trained staff 5 1.6 
 
9.3 NE users’ perceptions of pharmacy exchange service 
When asked to rate their local pharmacy’s exchange service, 37 of 250 respondents 
(14.8%) selected “good” and 16 (6.4%) “very good”, giving a combined “good or very 
good” response frequency of 21.2%.  Sixty respondents (24.0%) selected “middling”, 69 
(27.6%) “poor” and 68 (27.2%) “very poor”, giving a combined “poor or very poor” 
response frequency of 54.8%.   
The 66 people who did not supply any responses are assumed to never use pharmacy 
exchange services.  Note also that 188 (59.5%) of all 316 respondents had not bought 
needles and syringes from a pharmacy in the month prior to the survey. 
Survey respondents who had used pharmacy exchange services were asked “what would 
most improve pharmacies’ exchange services for you?”, and given a set of seven options 
from which to choose up to two.  The response frequencies are shown in table 9.2. 
 
Table 9.2  NE users’ preferred methods of improving pharmacies’ exchange services. 
 Option Number selecting Percentage (of 250) 
 better staff attitudes 155 62.0 
 lower prices for fits and other equipment 122 48.8 
 more anonymity/privacy 104 41.6 
 a greater range of injecting equipment 97 38.8 
 better discounts when old fits are returned 93 37.2 
 better-trained staff 76 30.4 
 provision of safer using information 35 14.0 
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The most popular method chosen by NE users to improve pharmacy exchange services was 
“better staff attitudes”, the third-most popular was “more anonymity/privacy”, and “better-
trained staff” was selected by a substantial minority.  Taken together, these three service 
quality options were chosen by 197 participants (78.8%).  “Lower prices” or “better 
discounts” were chosen by a combined total of 151 respondents (60.4%). 
Overall, these data show that few NE users are satisfied with the quality of the exchange 
service they receive at pharmacies (but the issues of survey bias away from pharmacy users 
– a group that may include people whose perceptions of pharmacy exchange service are 
excellent, and who never use NEs as a result - outlined in section 4.4.3 should be kept in 
mind). 
 
Recommendation: That the (perceived) problems of pharmacy staff attitudes towards 
needle exchange clients be addressed in a systematic way by the MoH, 
NENZ and the Pharmacy Guild; research into pharmacy exchange 
users’ perceptions of service would be a useful first step. 
 
9.4 Volunteer NE workers 
The recognition accorded to drug user groups through the Ministry of Health’s contracting 
process is a striking feature of New Zealand’s NSEP.  This recognition, and the autonomy 
given to the user groups in the running of the NEs, are undoubtedly powerful reasons for 
the strong feelings of ownership displayed by many NE staff, and help explain why so 
many unpaid and volunteer hours are worked. 
The issue of volunteer reimbursements is clearly a major one for NE managers, volunteers 
and trustees.  Many NEs reimburse their volunteers for the time they spend working in the 
NEs and on NE projects, a typical amount being $25 for a four-hour shift.  Such 
reimbursements are (reportedly) standard practice in many New Zealand charitable 
organizations; however, concern has arisen that the Inland Revenue Department may 
determine that volunteers who receive reimbursements for regular, scheduled periods of 
work are in fact employees and are thus tax-liable.  Such a ruling would mean that NEs 
would be hit with a double whammy in that they would face back-tax bills, and their 
volunteers would be forced to pay tax and thus be less motivated to offer their time in 
future.  The NEs could not afford to turn their volunteers into employees; the NEs I 
consulted operated on nearly 40% volunteer labour on average; none could afford to 
replace these free or low-paid hours with minimum-wage hours under their current 
contracts.  NE staff are vehemently opposed to becoming employees, as the concept of 
volunteerism is universally seen as fundamental to the operation of the NEs, bringing with 
it passion and a sense of ownership.   
Notwithstanding the overwhelmingly pro-volunteer views of NE staff, some perceived 
problems with the volunteer culture were described.  These included that volunteers do not 
have to commit to their work like they would to a job, and professionalism is not 
encouraged; the culture erodes management control, and the non-hierarchical structure of 
an organization which relies heavily on volunteers may lead to difficulty in implementing 
change. 
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On the positive side, the peer basis of New Zealand’s NEs is seen as important for 
education, both informal (over the counter and in the community) and formal (outreach and 
workshops).  Non-peers don’t always have credibility, so may not be able to convince 
people that their information is correct – and lacking direct experience, it may actually not 
be correct.  Volunteering is also seen as an important empowerment process for drug users, 
in that people learn that they’re still productive members of the community.  Volunteering 
involves the community, increases stores of specialist knowledge at the exchanges, and is a 
form of community development – volunteers gain skills which help them to find paid 
employment or simply go back into the community with increased knowledge about ways 
to reduce drug-related harm which they can continue to impart through their social 
networks. 
 
Recommendation: That the crucial role of NE volunteers in New Zealand’s NSEP be 
affirmed, and that any resolution of the “reimbursement problem” 
must not jeopardise volunteers’ input to the programme. 
 
9.5 Electronic dispensers 
Electronic dispensers (vending machines) enable sterile syringes and other equipment to be 
provided to IDUs without any human interaction.  Several countries, including France, 
Switzerland, Germany and Australia use syringe vending machines to varying extents.  The 
advantages of vending machines include reduced staffing costs, 24 hour access, anonymity 
for the user, and provision of services to IDUs who might not otherwise be reached at all 
and may be at extremely high risk (Strathdee and Vlahov, 2001).  Obadia et al (1999) 
found that IDUs using vending machines were significantly younger, more likely to be 
homeless, HIV+, in drug treatment and share needles.   
The vending machine at ADIO Trust (Auckland) is a typically innovative New Zealand 
solution to the problems of providing exchange services after hours.  At the end of each 
day, a solid steel mobile unit containing the vending machine is wheeled into a steel frame 
fitted to the existing wooden frame of the front doorway and locked there.  When not in 
place during office hours, the original door functions normally.  This design enables 
exchange services to continue after hours in a secure manner, without the need to make 
structural alterations which may not be approved by leasors.  The machine offers a full 
range of sterile injecting equipment, and safer injecting educational material is included 
with each item. 
Many of those consulted, including NENZ, were in favour of the installation of more 
electronic dispensers to provide after-hours access to needle exchange services in urban 
centres.  They were seen as valuable for improved security, reducing the occurrence of 
break-ins aimed solely at obtaining injecting equipment (a significant problem at several 
NEs).  Some saw electronic dispensers as possible solutions to the economics and 
anonymity problems involved in servicing small communities.  
 
Recommendation: That consideration be given to expanding the use of electronic 
dispensers at NEs to provide after-hours exchange services. 
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9.6 IDU education and health promotion 
During a telephone conversation with Dr Richard Meech, chair of New Zealand’s AIDS 
Medical and Technical Advisory Committee (AMTAC) in late June, he expressed the view 
that NEs should address the issue of safe disposal of needles and syringes by public means 
in their IDU education activities.  Dr Meech pointed out that the national return rate (to 
NEs or pharmacies for destruction) of around 50% meant that hundreds of thousands of 
syringes were being disposed of in domestic and public waste and in other ways (such as 
the sewerage system or burial) which potentially put members of the public at risk of 
needlestick injury.  It is true that in New Zealand syringes are not permitted in domestic 
rubbish, but a problem limitation approach acknowledges that this is happening and is 
going to continue, so the best course is to advise IDUs on the best disposal methods under 
the circumstances.  Obviously return to an NSP or pharmacy for destruction should remain 
the priority method of disposal. 
During the consultation period I inspected the health promotion materials produced by 
NENZ and the NEs, and was extremely impressed by their range and quality.  Even the 
more mundane items such as posters and pamphlets were frequently fresh and innovative 
in their approaches, and often tailored to respond to specific local needs or drug issues.  
Videos and other information resources are also of high quality.  The NENZ website is a 
tremendously useful resource, but requires some updating (underway during the Review). 
 
Recommendation: While return of used needles and syringes to NEs or pharmacies for 
destruction should remain first priority, NEs should address the issue 
of safe disposal of needles and syringes by public means in their IDU 
education activities in order to reduce visibility of needles and 
syringes in public places and risk of needlestick injury.   
 
9.7 Safety in pharmacies and exchanges 
The fact that “every now and then you get somebody who is really in your face and does 
upset you greatly” (Maree Jensen, Pharmacy Guild, pers comm.) is an unfortunate fact of 
life for people involved in the NSEP.  A Wanganui pharmacy stopped participating in the 
NSEP in early 2002 after two incidents involving IDUs on its premises, and it is clear that 
perceptions of unacceptable difficulties resulting from delivering exchange services is a 
major deterrent to the recruitment of new pharmacies to the NSEP.  Maree Jensen and 
others consulted viewed the apparent escalation of New Zealand’s amphetamine scene as 
likely to increase the frequency of unpleasant interactions between NSEP clients and staff. 
 
9.8 Training for pharmacy and exchange staff  
Both Euan Galloway and Maree Jensen (Pharmaceutical Society and Pharmacy Guild 
respectively) were enthusiastic about development of a defined set of training procedures 
for pharmacy staff as a way of improving staff confidence about needle exchange, 
improving exchange services and reducing unpleasant interactions with NSEP clients.  
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These would be best administered by NEST during brief, pre-arranged, on-the-job training 
sessions with pharmacy staff. 
Many NE staff regarded training as very important for workers and volunteers, in such 
areas as infection control, dealing with users, emergency procedures, information 
provision.  NE managers saw benefits in business skills and human resources management 
training for improved financial security.  Several NE managers talked about a national 
template for NE worker training, and formal acknowledgement of skills through 
certification, which would raise self-esteem and improve employability.  NENZ was seen 
as the logical vehicle for organising training. 
 
Recommendation: That training modules for pharmacy staff be developed by NENZ and 
NEST in consultation with the Pharmacy Guild and Pharmaceutical 
Society, promoted by them, and delivered by NEST staff.   
 
9.9 Vaccination, testing and counselling 
Two of the exchanges whose staff I consulted (Nelson and DIVO) are already providing 
some of these services.  Both are entirely reliant upon the goodwill of local GPs.  At 
Nelson, two local GPs provide free hepatitis A, B and C and HIV testing and hepatitis 
A&B vaccines on a sessional basis.  In Dunedin, Rosemary Friend offers counselling and 
testing for hepatitis A, B and C and HIV two mornings a week.  
In the survey of NE users, hepatitis C and HIV testing, hepatitis A & B vaccinations and 
counselling were quite high on the list of ways IDUs thought NEs could improve their 
services (4th, 7th and 8th, selected by 25.6%, 18.8% and 14.6% respectively).   
 
Recommendations: That GP training in New Zealand include a component on aspects of 
illicit drug use, including the NSEP (its rationale and operation) and 
methadone maintenance programmes. 
That the Ministry of Health liaise with the New Zealand Medical 
Association about encouraging GPs to work with their local NE to 
provide improved access to testing, counselling and primary 
healthcare services. 
 
9.10 Some impressions from the consultations 
Throughout the consultation process, the passion and commitment that so many NE staff 
bought to their work was obvious.  The peer ethos and the extraordinary contribution made 
by peer volunteer workers to the programme is clearly vital to the operation of the NSEP in 
its current form.  The self-reliance and innovative thinking displayed by NE staff was also 
impressive.  One example is the manufacture and sale of Velcro tourniquets by Rodger 
Wright Centre volunteers in response to the realisation that commercially-available 
products were too expensive for many IDUs and the lack of tourniquets was leading to 
increased health risks.  Some NEs – recognising the relatively high prevalence of piercing 
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among their clients - carry sterile piercing equipment so that their clients can perform 
piercings with reduced risk of BBV transmission.  Many NEs independently raise funds for 
activities beyond basic exchange services, by making applications to other charitable trusts 
and foundations.  There is a community spirit to needle exchange in New Zealand which 
should be regarded as a valuable asset. 
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10. Prison issues 
Prisoners are one of the key risk groups for transmission of blood-borne viruses, and in 
particular, prisons are one of the engines of the hepatitis C epidemic (Crofts et al, 2001).  
Drug offences are one of the most common reasons for incarceration in western countries, 
and many prisoners committed drug-related and other crimes to support their drug habits; 
therefore, large proportions of prison entrants are IDUs.  Prevalence of antibody to the 
hepatitis C virus among IDUs in New Zealand was most recently measured at 53%, and 
HIV 0.9% (Kemp and MacDonald, 1999).  Once inside, many IDUs - and some people 
who had never previously injected – inject drugs, almost invariably with well-used and 
shared equipment.  Other blood exposures also contribute to transmission within prisons, 
such as tattooing with inadequately disinfected equipment. 
High prevalence of hepatitis C among prison inmates is well documented around the 
world, and much lower prevalences of HIV have also frequently been reported.  In 
California in 1994, 39.4% of male inmates (Spaulding et al, 1999), in Ireland, 22% of 718 
inmates (Long et al, 2001), and in the UK, 31% of prisoners with a history of IDU were 
found to be HCV antibody-positive (Weild et al, 2000).  In Australia, prevalences of 37% 
(Butler et al, 1997) and 39% (Crofts et al, 1995) among inmates have been reported, rising 
to 66% and 64% respectively among prisoners who had a history of IDU.  Long et al 
(2001) measured an HIV prevalence in Irish prisoners of 2%; Spaulding et al (2002) 
estimated that up to a quarter of all people living with HIV infection in the United States 
enter a prison each year; in a European multi-centre study, Rotily et al (2001) found an 
HIV prevalence of 4% among IDUs and 1% among non-IDUs.  Sharing needles and 
syringes is much more common in prison than in the community, and needles may be used 
multiple times by multiple individuals, making transmission within prison more likely per 
sharing event (Crofts et al, 1995). 
In New Zealand, the situation appears little different to that in other countries.  Couper and 
Croxson (1993) investigated a suspected outbreak at an Auckland maximum security 
prison, and eight of 31 prisoners tested (25.8%) were found to be HCV-seropositive and 
viraemic.  Brunton (1994) reported that of 270 inmates of a Christchurch medium security 
prison, just over half (52%) had ever injected drugs and around a third (31%) had injected 
while in prison.  Just under a quarter (23%) of the prisoners tested were anti-HCV positive.   
As this review demonstrates, the NSEP has been effective in preventing HIV and HCV 
transmission among IDUs in the New Zealand community, and prisoners are highly likely 
to have histories of IDU; thus the most pragmatic course of action would be to extend the 
NSEP into New Zealand’s prisons.  Provision of sterile injecting equipment to prisoners 
has been trialled in Switzerland, with apparently excellent outcomes (Nelles and Harding, 
1995).  Unfortunately, despite the benefits to public health that would result such 
initiatives are frequently unpalatable to governments due to their potential for political 
misrepresentation (“encouraging drug use by convicted criminals”, etc).  Nevertheless, the 
topic continues to be raised, most recently in Australia by the Australian National Council 
on Drugs in their position paper on Needle and Syringe Programs (Australian National 
Council on Drugs, 2002).  Their recommendations on drug-related BBV prevention in 
prisons were: 
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1. That comprehensive and appropriate education and information programs on drug use, 
hepatitis C and other blood borne viral infections be provided to all prisoners and 
juvenile detainees, with an emphasis on new entrants, in all Australian prisons and 
juvenile detention centres. 
2. That appropriate drug use and related education programs for families of prisoners and 
juvenile detainees be introduced in each jurisdiction. 
3. That bleach be made freely available and accessible in all Australian prisons and 
juvenile detention centres, as a matter of urgency. 
4. That each jurisdictional department responsible for the management of prisons and 
juvenile detention centres, in consultation with staff, health authorities and relevant 
community-based organisations, develop occupationally safe and culturally appropriate 
policies, protocols and procedures regarding the introduction of trial needle and syringe 
programs within at least one of its prisons and juvenile detention centres. 
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11. Conclusions 
 
Effectiveness 
Most of the scientific evidence shows that needle and syringe programmes worldwide are 
effective in reducing prevalence and/or incidence of HIV infection in injecting drug users.  
New Zealand enjoys one of the lowest prevalences of HIV infection in IDUs (0.9%) 
among more developed nations, lower even than countries such as Australia and The 
Netherlands which have (arguably) employed more comprehensive and intensive needle 
exchange strategies.  It is estimated - by adapting the work of Health Outcomes 
International et al (2002) to suit New Zealand - that had the NSEP not been introduced, by 
the end of 2001 New Zealand would have had 1,031 extra people living with HIV or 
AIDS, and an extra 20 people would have died following an HIV infection, and a further 
1,454 would be living with HCV. 
A gradual decline has occurred in the prevalence of needle-sharing among New Zealand 
IDUs since the mid-80s, and the most recent survey data show a substantial reduction in 
prevalence of sharing, from 50 to six per cent (in the month prior to survey) between 1994 
and 2002.  While proving a direct link between NSEP activities and behaviour is difficult, 
the strong implication is that the NSEP has reduced needle-sharing among IDU. 
The NSEP appears to be effective in reaching New Zealand’s IDUs, with less than 5% of 
survey respondents reporting frequent difficulty in obtaining injecting equipment.  Over 
90% of respondents perceived little or no difficulty with access due to distance from an 
outlet.  Nevertheless, the Review identified several regions which were under-serviced by 
NEs, including Auckland, Southland and the West Coast of the South Island.  There are 
also some concerns about the NSEP’s reach in terms of Maori and smaller ethnic groups. 
 
Efficiency 
A cost/benefit analysis was conducted based on the estimated numbers of HIV and HCV 
infections prevented by NSEP introduction, annual treatment costs for people with HIV or 
HCV disease, and annual investment in the NSEP.  Treating the 1,031 extra people living 
with HIV/AIDS and the 673 diagnosed with chronic HCV infections by the end of 2001 
had the NSEP not been introduced would have added $35,678,516 to New Zealand’s total 
healthcare outlay between 1989 and 2001, while total expenditure on the NSEP over that 
period was estimated at $10,644,588.  Thus the net benefit due to the NSEP – based on 
HIV and HCV infections prevented between 1988 and 2001 – is $25,033,928.  Every $1 
spent on New Zealand’s NSEP between 1988 and 2001 saved an estimated $3.35 in 
healthcare costs accruing in that period alone.  Extending the projections forward until all 
the extra people infected with HIV or HCV between 1988 and 2001 were estimated to have 
died produces a total net benefit of $202,274,686, meaning every $1 spent on the NSEP in 
that period yielded $20.00 in lifetime treatment costs avoided. 
Each needle and syringe distributed by New Zealand’s NSEP costs approximately $0.90, 
making the programme about as efficient in terms of unit cost as the Australian state of 
Victoria, but less efficient than the average of all Australian state programmes ($0.74).  
Economies of scale and population density are probable explanations. 
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Service delivery 
The NE users’ survey revealed that NE users were very happy with the service they 
received at NEs (96.5% selecting “good” or “very good”).  The most popular options for 
improving service were one-for-one (new for old) syringe exchange and out-of-hours 
electronic syringe dispensers. 
NE users were less satisfied with pharmacy exchange services, with 21.2% rating it as 
good or very good.  Better staff attitudes (towards IDUs) and lower prices of injecting 
equipment were the options favoured for improved service. 
 
Other issues 
In the consultations, nearly universal support was expressed for removing the anomaly of 
possession of injection equipment being an offence under the Misuse of Drugs Act [section 
13(1)(aa)] while a defence exists under the Health (Needles and Syringes) Regulations 
1998. 
One for one (new for old) needle and syringe exchange is the mode of service favoured by 
all NE staff.  Experience to date with one-for-one has been very positive in terms of 
increasing distribution of new and return of used equipment, and reducing syringe re-use.  
The Review’s survey of NE users found that IDUs attending NEs offering one-for-one 
exchange reported significantly lower prevalences of needle and syringe sharing and re-use 
than IDUs attending other NEs. 
The concept of providing syringe disposal bins in public places was supported by many of 
those consulted as a way of enabling safer disposal and reducing the visible aspects of 
illicit drug use. 
Electronic dispensers (vending machines) currently used by NEs in Auckland and 
Christchurch to provide after-hours service are working well, and were frequently 
nominated as a potential method of improving the reach of the NSEP. 
Training for pharmacy staff and NE workers and volunteers was widely approved as a 
means of increasing the effectiveness and efficiency of the programme. 
 
New Zealand’s NSEP is both effective and efficient, particularly with respect to its core 
aim - prevention of HIV infections among injecting drug users. 
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12. Recommendations 
1. That the effectiveness and efficiency of New Zealand’s NSEP be acknowledged. 
2. That New Zealand’s government and community recognise the vital role of the 
NSEP in preventing HIV infections. 
3. That consideration be given to opening a second peer-based NE in Auckland, to 
bring per-capita service coverage closer to the level which exists elsewhere in New 
Zealand. 
4. That consideration be given to improving NSEP coverage on the South Island’s 
west coast and Southland by opening branch NEs and/or upgrading and expanding 
existing pharmacy outlets. 
5. That consideration be given to increasing the reach of the NSEP by enabling and/or 
encouraging the provision of needle exchange services through existing health 
service infrastructure, such as Community Health Centres and Sexual Health 
clinics. 
6. That consideration be given to expanding the use of electronic dispensers at NEs to 
provide after-hours exchange services. 
7. That the costs and benefits which would result from the introduction of free one-
for-one (new for old) needle and syringe exchange in New Zealand be formally 
investigated. 
8. That the crucial role of NE volunteers in New Zealand’s NSEP be affirmed, and 
that any resolution of the “reimbursement problem” must not jeopardise volunteers’ 
input to the programme. 
9. That New Zealand’s parliament approve the proposed amendment to the Misuse of 
Drugs Act which would remove the offence of possession of needles and syringes 
legally obtained through the NSEP.  
10. That the (perceived) problems of pharmacy staff attitudes towards needle exchange 
clients be addressed in a systematic way by the Ministry of Health, NENZ and the 
Pharmacy Guild; research into pharmacy exchange users’ perceptions of service 
would be a useful first step. 
11. That the Pharmaceutical Society provide NEST with details of pharmacy closures, 
openings, and changes of ownership on a monthly basis. 
12. While return of used needles and syringes to NEs or pharmacies for destruction 
should remain first priority, NEs should address the issue of disposal of needles and 
syringes, by means other than return to NEs or pharmacies, in their IDU education 
activities in order to reduce visibility of needles and syringes in public places and 
risk of needlestick injury.   
13. That training modules for pharmacy staff be developed by NENZ and NEST in 
consultation with the Pharmacy Guild and Pharmaceutical Society, promoted by 
them, and delivered by NEST staff.   
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14. That GP training in New Zealand include a component on aspects of illicit drug 
use, including the NSEP (its rationale and operation) and methadone maintenance 
programmes. 
15. That the Ministry of Health liaise with the NZMA about encouraging GPs to work 
with their local NE to provide improved access to testing, counselling and primary 
healthcare services. 
16. That basic training for NZ police include a short session on New Zealand’s harm 
minimisation policy and the NSEP.  NENZ should liaise with police to achieve this 
goal. 
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Appendix 1 - Terms of Reference for the Review 
 
 
 
(see overleaf) 
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Terms of reference for the review of the Needle and Syringe 
Exchange Programme. 
 
1. Introduction 
 
These terms of reference describe the review of the needle and syringe exchange 
programme (NSEP) review.   
 
2. Aim of the review  
 
To ensure the NSEP is working in the most effective and efficient way possible 
within available resources.  
 
3. Background 
 
Needle exchange was legalised in New Zealand through the introduction of the 
Health (Needles and Syringes) Regulations 1987 which allowed the sale of 
needles and syringes to injecting drug users provided their sale is part of the 
NSEP.  The regulations also create a legal defence to the charge of possession of 
injection equipment, which remains an offence under the Misuse of Drugs Act 
[section 13(1)(aa) of the Act refers].  
 
The programme allows pharmacists, medical practitioners and other authorised 
representatives to provide clean needles and syringes.  When the initial 
programme was established, needles and syringes were sold for a price set by the 
Director-General of Health at that time $1 (inclusive of GST) per needle and 
syringe.  These regulations were subsequently amended in 1998 removing the 
requirement for the Director-General to set the price for needles and syringes and 
these can now be sold at any price.   
 
The strategies of the programme are: 
 
• The sale and distribution of new, and therefore clean, injection equipment. 
• Safe disposal of used needles and syringes. 
• Free distribution of safer sex equipment to NSEP clients. 
• Provision of clear simple messages about the transmission of diseases and 
safer drug use techniques to every person using the NSEP. 
 
The NSEP is based on a philosophy of harm reduction rather than abstention; that 
is to minimise the potential harm from injecting drug use rather than attempting to 
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curtail this activity.  This is consistent with the National Drug Policy’s emphasis on 
harm minimisation. 
 
The harm reduction model aims to modify behaviour to minimise the spread of HIV 
and other blood-borne diseases.  The NSEP, while not condoning the use of illegal 
drugs, accepts that drug use continues to occur despite its legal prohibition. 
 
4. Review focus 
 
Regulatory Issues  
 
Including:   
 
• Offence of self administration  
• Decriminalisation of possession of injection equipment Sharps disposal bins 
in public areas (e.g. toilets) 
• One for one exchange  
• Simplified outlet approval processes  
 
Economic sustainability and programme structure 
 
Including:  
 
• Staff retention and use of "volunteers" 
• Methods of staff payment and reimbursement 
• Implication of employment relation act  
• Price efficiency/ equity /fairness/sustainability 
 
 
Service Delivery Issues 
 
Including: 
 
• Levels of health education and promotion content 
• Safety in pharmacies and exchanges  
• Service availability  
• Other community generated sharps waste, for example diabetic sharps 
 
Quality issues  
 
Including:  
 
• Service benchmaking or minimum levels of service  
• Training for pharmacy and exchange staff  
 
 
Programme development 
 
Including: 
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• Voluntary hepatitis A and B vaccination  
• Mobile services' 
• Primary care health clinics 
• Social services for IDU 
 
Prison issues  
 
Including:  
 
• Harm minimisation in prisons; methadone maintenance 
• Prevention issues; bleach, condoms, needle exchange availability  
• Health promotion for both staff and inmates. 
 
 
5. Review methodology 
 
The reviewer / review team will undertake a detailed analysis of the programme.  
This analysis will include consultation with and information gathering from the 
stakeholders of the NSEP, that is, the Ministry of Health, Needle Exchange New 
Zealand, the Pharmacy Guild, and the Pharmaceutical Society.   
 
6. Publication of results 
 
A written report will be presented to the Ministry of Health on 30 June 2002.  This 
will subsequently be distributed to the stakeholders in the NSEP. 
 
7. Timeframe 
 
Start date:  As soon as the reviewer is appointed  
End date:  30 June 2002 
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Appendix 2 - NE user’s questionnaire 
 
 
(see overleaf) 
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This survey is part of an independent review of Needle and Syringe Exchange in New Zealand.  
We want your views on the exchange programme and how it might be improved. 
Participation is voluntary and anonymous. 
Please write a response where indicated, or tick the most appropriate box. 
 
 
1. What is your age in years? _____ 
2. What is your gender? ٱ Male ٱ Female ٱ Transsexual 
3. What is your ethnicity? ٱ Maori ٱ NZ / European ٱ Pacific Islander 
  ٱ Asian ٱ Other ______________________ 
 
4. On average, how many times per week have you injected drugs recently? 
 ٱ 1 or less ٱ 2-3 ٱ 4-7 ٱ 8-13 ٱ 14 or more 
4a. How many times do you usually re-use a fit? _____ 
4b. How many times have you used someone else’s used fit in the past month? _____ 
4c. Which drug have you injected ٱ Morphine / MST ٱ Methadone 
 most often in the past month?  ٱ Speed ٱ Homebake 
   ٱ Benzos (eg.Temazepam) ٱ Ritalin 
  ٱ Other ________________________ 
 
5. How many times have you got fits from an exchange in the past month? _____ 
 ٱ 1-2 ٱ 3-4 ٱ 5-8 ٱ 9-12 ٱ 13 or more 
6. How many times have you bought fits from a pharmacy in the past month? _____ 
 ٱ 1-2 ٱ 3-4 ٱ 5-8 ٱ 9-12 ٱ 13 or more 
 
7. Do you ever find it hard to get fits when you want them? ٱ Yes      ٱ No 
7a. (If YES above) How often have you found it hard to get fits over the past month?  
 ٱ never ٱ sometimes ٱ half the time ٱ most times ٱ always 
7b. Why do you find it hard to get fits? (You can tick more than one) 
 ٱ Exchange’s hours don’t always suit me ٱ Nearest pharmacy’s hours don’t suit me 
 ٱ I don’t like being seen at outlets ٱ I live a long way from any outlets 
 ٱ prices of injecting equipment are too high ٱ other _________________________ 
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7c. If you find it hard to get new fits, does this mean you have to 
 re-use or share fits more often? ٱ Yes      ٱ No 
8. If you don’t return all your fits, why not? ٱ fear of arrest ٱ child safety 
 (You can tick more than one)  ٱ discounts too small ٱ it’s a hassle 
   ٱ Other ______________________ 
9. How do you rate your local exchange’s service? 
 ٱ Very poor ٱ Poor ٱ Middling ٱ Good ٱ Very good 
9a. What would most improve the exchange’s service for you?  
 (Please tick up to four options) 
 ٱ a lower price for fits ٱ a greater range of injecting equipment 
 ٱ lower prices for other injecting equipment ٱ free one-for-one (new for used) exchange 
 ٱ out-of-hours fit vending machines ٱ longer opening hours 
 ٱ more information about hepatitis C & HIV ٱ on-site hepatitis C and HIV testing 
 ٱ more or better general healthcare info ٱ more or better harm reduction info 
 ٱ on-site hepatitis A & B vaccinations ٱ on-site counselling services 
 ٱ more time for staff to advise & refer ٱ better-trained staff 
 ٱ better staff attitudes  ٱ other _________________________ 
 
10. How do you rate your nearest pharmacy’s exchange service? 
 ٱ Very poor ٱ Poor ٱ Middling ٱ Good ٱ Very good 
10a. What would most improve pharmacies’ exchange services for you? 
 (Please tick up to two options) 
 ٱ lower prices for fits and other equipment ٱ better discounts when old fits are returned 
 ٱ a greater range of injecting equipment ٱ provision of safer using information 
 ٱ better-trained staff ٱ better staff attitudes 
 ٱ more anonymity / privacy ٱ other _________________________ 
 
11. Finally, if you have any other ideas about how needle exchange in New Zealand 
(through NEs or pharmacies) could help drug users use more safely, please tell us. 
 
____________________________________________________________________________ 
____________________________________________________________________________ 
____________________________________________________________________________
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Appendix 3 - Call for public submissions 
 
 
 
 
 
 
 
NZ Needle and Syringe 
Exchange Programme Review 
The Centre for Harm Reduction (part 
of the Burnet Institute, Australia) is 
reviewing New Zealand’s Needle 
and Syringe Exchange Programme 
(NSEP).  The review’s aim is to 
ensure the NSEP is working in the 
most effective and efficient way 
possible within available resources.   
Submissions which address the 
review’s aim and terms of reference 
(available at www.chr.asn.au, or 
from the address below) must be sent 
by COB Friday 7th June 2002 to: 
NZ NSEP Review 
c/o Brendon Baker 
Ministry of Health 
P.O. Box 5013, Wellington 
Fax: (04) 496 2340 
Email: Brendon_Baker@moh.govt.nz 
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Appendix 4 - List of contacts 
 
Campbell Aitken 
Centre for Harm Reduction 
The Burnet Institute 
Commercial Road 
Melbourne  Victoria  
AUSTRALIA    3181 
Tel: 61 03 9282 2114 
aitkenc@burnet.edu.au 
 
Mike Arnerich 
Detective Senior Sergeant 
Wellington Metro Organised Crime Unit 
180 Molesworth St 
Wellington 
Mike.Arnerich@police.govt.nz 
 
Kelly Auerbach 
Manager, Drugs Project 
202 Willis Street 
Wellington 
Tel: 04 382 8404 
DHDPWellington@xtra.co.nz 
 
Brendon Baker 
Public Health Directorate 
New Zealand Ministry of Health 
Old Bank Building 
cnr Lambton Quay and Willis St 
Tel: 64 (04) 496 2000 
Brendon_Baker@moh.govt.nz 
 
Michael Baker 
Public Health Physician 
Department of Public Health 
Wellington School of Medicine and 
Health Sciences 
PO Box 7343, Wellington South 
Tel: 64 04 385 5999 
michael.baker@wnmeds.ac.nz 
 
Karen Blacklock 
Manager, ADIO Trust 
7A Maidstone Street 
Ponsonby, Auckland 
Tel: 09 376 8090 
adio@ihug.co.nz 
 
Peter Barron 
Community Pharmacist 
Senior Teaching Fellow 
School of Pharmacy 
University of Otago 
Dunedin 
Tel: 03 477 6556 
peter.barron@xtra.co.nz 
 
Cheryl Brunton 
Senior Lecturer in Public Health 
Department of Public Health & General 
Practice 
Christchurch School of Medicine and 
Health Sciences 
PO Box 4345 
Christchurch 
Tel: 03 364 3625 
cheryl.brunton@chmeds.ac.nz  
 
Nick Crofts 
The Burnet Institute 
Commercial Road 
Prahran  Victoria  
AUSTRALIA    3181 
Tel: 61 03 9282 2169 
crofts@burnet.edu.au 
 
Greg Dore 
National Centre in HIV Epidemiology 
and Clinical Research 
376 Victoria Street 
Darlinghurst  NSW  2010 
Australia 
Tel: 61 02 9332 4648 
Fax: 61 02 9332 1837 
gdore@nchecr.unsw.edu.au 
 
Stephen Farquhar 
(Chair of the DIVO Trust) 
Research Coordinator 
CG Surgical 
Otago Polytechnic 
Harbour Terrace 
Dunedin 
Tel: 03 477 2840 
Stephen.farquhar@cgsurgical.co.nz 
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J. Paul Fawcett 
Associate Dean (Research) 
School of Pharmacy 
University of Otago 
Dunedin 
03 479 7290 
paul.fawcett@stonebow.otago.ac.nz 
 
Helen Fraser 
The Burnet Institute 
Commercial Road 
Prahran  Victoria  
AUSTRALIA    3181 
Tel: 61 03 9282 2169 
fraser@burnet.edu.au 
 
Euan Galloway  
Pharmaceutical Society 
Pharmacy House 
124 Dixon Street 
WELLINGTON  
Tel: 04 802 0030 
e.galloway@pharmacy-house.org.nz 
 
Kevin Hague 
Executive Officer, NZ AIDS Foundation 
31-35 Hargreaves Street 
Ponsonby, Auckland 
Tel: 09 303 3124  
anne.carson@nzaf.org.nz 
 
Paula Harris 
Manager, Timaru Exchange 
88 Staffords Street 
Timaru 
Tel: 03 688 8158  
timaru.nex@xtra.co.nz 
 
Charles Henderson 
National Manager 
Suite 34, Cashel Chambers  
224 Cashel Street 
Christchurch 
Tel: 64 3 366 9403 
charles@needle.co.nz 
 
Bill Jang 
Manager, Hepatitis C Resource Centre 
224 Cashel Street 
Christchurch 
Tel: 03 366 3608 
hcv@xtra.co.nz 
 
Maree Jensen 
Pharmacy Guild of NZ 
Maree Jensen Pharmacy 
1011 Dominion Rd 
Mt Roskill 
Tel: 09 620 9487 
mjensen@ihug.co.nz 
 
Robert Kemp 
Queensland Needle Availability support 
program 
Qld Health Department 
Tel: (07) 3896 3848  
robert_kemp@health.qld.gov.au 
 
Gary Knowles 
Detective Inspector 
National Bureau of Criminal Intelligence 
180 Molesworth St 
Wellington 
gary.knowles@police.govt.nz 
Tel: 04 470 7303 
 
Hilary Lawrence 
Manager, DIVO 
17A St Andrews Street  
Dunedin 
Tel: 03 479 2300 
divo@es.co.nz 
 
Gerry Macphail 
Manager, NINE 9 
Bank Street 
09 430 6524 
Whangarei 
nine@ihug.co.nz 
 
Paul Marriott-Lloyd 
Advisor, Strategic Policy Group 
Office of the Commissioner 
New Zealand Police 
180 Molesworth St 
Wellington 
Tel: 64 4 474 9505 
Paul.Marriott-Lloyd@police.govt.nz 
 
Richard Meech 
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c/o Hawkes Bay Hospital 
Private Bag, Hastings 
Tel: 64 06 878 8109 
Email:richard.meech@hawkesbaydhb.govt.nz 
 
Richard Schurr 
Detective Sergeant 
National Drug Intelligence Bureau 
180 Molesworth St 
Wellington 
Tel: 04 470 7244 
richard.schurr@police.govt.nz 
 
Geoff Robinson 
Senior Consultant Physician 
Opioid Substitution Service 
36 Tacy Street 
Kilbirnie, Wellington 
Tel: 494 9170 
geoff.robinson@ccdhb.org.nz 
 
Ian Smith 
Regional Coordinator 
New Zealand AIDS Foundation 
PO Box 21285, Edgeware 
Christchurch 1 
Tel: 03 365 2477 
ian.smith@nzaf.org.au 
 
Maggie Treweek 
Manager, Rodger Wright Centre 
10 Liverpool Street 
Christchurch 
Tel: 03 365 2293 
rwc@xtra.co.nz 
 
Owen Westcott 
owenwestcott@doh.health.nsw.gov.au 
 
Donelle Thompson  
Manager, NEWS Trust 
487 Anglesea Street 
07 834 4309 
Hamilton 
news_trust@xtra.co.nz 
 
Drew Thomas  
Mid-Central Health 
11 Heretaunga Street 
06  
Palmerston North  
dhdp.pn@xtra.co.nz 
 
Jan Thomas 
Timaru Exchange 
88 Staffords Street 
Timaru 
Tel: 03 688 8158 
timaru.nex@xtra.co.nz 
 
Lynne Waller 
Manager, Niche 
16 Nile Street 
03 546 8170 
West Nelson 
niche@ts.co.nz 
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Appendix 5 – Data tables 
 
1. HIV/AIDS cases and deaths in IDUs per annum prevented by NSEP introduction. 
2. HIV/AIDS cases per annum by disease stage prevented due to NSEP introduction. 
3. HCV cases in IDUs per annum prevented by NSEP introduction. 
4. HCV cases per annum prevented due to NSEP introduction by disease stage. 
5. Estimated public expenditure on New Zealand’s NSEP ($). 
6. Annual treatment costs per HIV infection by disease stage ($). 
7. Annual treatment costs per HCV infection by disease stage ($). 
8. Estimated annual and cumulative cost/benefits of the NSEP ($). 
 
   
 78 
1. HIV/AIDS cases and deaths in IDUs per annum prevented by NSEP introduction.  
 
   HIV/AIDS    Deaths  
Year 
 Upper 
bound Estimate 
Lower 
bound 
Upper 
bound Estimate
Lower 
bound 
1981  0 0 0  0 0 0 
1982  0 0 0  0 0 0 
1983  0 0 0  0 0 0 
1984  0 0 0  0 0 0 
1985  0 0 0  0 0 0 
1986  0 0 0  0 0 0 
1987  0 0 0  0 0 0 
1988  0 0 0  0 0 0 
1989  4 2 1  0 0 0 
1990  13 7 2  0 0 0 
1991  28 16 4  0 0 0 
1992  52 30 8  0 0 0 
1993  87 50 13  1 0 0 
1994  139 80 21  1 1 0 
1995  212 122 32  3 2 0 
1996  315 181 47  6 3 1 
1997  459 264 69  9 5 1 
1998  660 379 99  14 8 2 
1999  934 537 140  20 11 3 
2000  1304 750 195  27 15 4 
2001  1793 1031 268  35 20 5 
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2. HIV/AIDS cases per annum prevented due to NSEP introduction by disease stage. 
(Note that due to rounding, figures for the disease stages do not always add to the HIV/AIDS total.) 
 
Year 
 
HIV/AIDS 
HIV CD4 
>500 
HIV CD4 
<500 AIDS 
Total 
deaths 
1981  0 0 0 0 0 
1982  0 0 0 0 0 
1983  0 0 0 0 0 
1984  0 0 0 0 0 
1985  0 0 0 0 0 
1986  0 0 0 0 0 
1987  0 0 0 0 0 
1988  0 0 0 0 0 
1989  2 2 0 0 0 
1990  7 7 0 0 0 
1991  16 15 1 0 0 
1992  30 27 2 0 0 
1993  50 45 5 1 0 
1994  80 69 9 2 1 
1995  122 102 17 3 2 
1996  181 148 28 5 3 
1997  264 211 45 8 5 
1998  379 298 70 11 8 
1999  537 414 107 16 11 
2000  750 568 160 22 15 
2001  1031 767 235 29 20 
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3. HCV cases prevented due to NSEP introduction.  
 
Year 
 Upper 
bound HCV 
Lower 
bound 
1981  0 0 0
1982  0 0 0
1983  0 0 0
1984  0 0 0
1985  0 0 0
1986  0 0 0
1987  0 0 0
1988  0 0 0
1989  123 70 18
1990  293 168 44
1991  462 265 69
1992  632 363 95
1993  806 464 121
1994  986 567 147
1995  1,173 674 175
1996  1,368 786 204
1997  1,573 904 235
1998  1,791 1,029 268
1999  2,022 1,162 302
2000  2,268 1,303 339
2001  2,531 1,454 378
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4. HCV cases per annum prevented due to NSEP introduction by disease stage. 
(Note that due to rounding, figures for disease stages do not always add to the chronic HCV total.) 
 
Year 
 Total 
living with 
HCV 
 
Total 
chronic Stage 0/1 Stage 2/3 Cirrhosis
HCC 
incidence 
Liver 
failure 
incidence 
1981  0  0 0 0 0 0 0 
1982  0  0 0 0 0 0 0 
1983  0  0 0 0 0 0 0 
1984  0  0 0 0 0 0 0 
1985  0  0 0 0 0 0 0 
1986  0  0 0 0 0 0 0 
1987  0  0 0 0 0 0 0 
1988  0  0 0 0 0 0 0 
1989  70  53 52 1 0 0 0 
1990  168  126 123 3 0 0 0 
1991  265  199 192 7 0 0 0 
1992  363  273 260 12 0 0 0 
1993  464  348 328 19 1 0 0 
1994  567  425 398 26 1 0 0 
1995  674  505 469 35 2 0 0 
1996  786  590 543 44 2 0 0 
1997  904  678 619 55 3 0 0 
1998  1,029  772 700 68 4 0 0 
1999  1,162  871 784 81 6 0 0 
2000  1,303  978 874 96 8 0 0 
2001  1,454  1,091 969 112 10 0 0 
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5. Estimated public expenditure on New Zealand’s NSEP ($). 
 
Year Annual expenditure Cumulative expenditure 
1981 0  
1982 0 0 
1983 0 0 
1984 0 0 
1985 0 0 
1986 0 0 
1987 0 0 
1988 350,830 350,830 
1989 389,811 740,641 
1990 433,123 1,173,764 
1991 481,248 1,655,012 
1992 534,720 2,189,732 
1993 594,133 2,783,865 
1994 660,148 3,444,013 
1995 733,498 4,177,511 
1996 814,998 4,992,508 
1997 905,553 5,898,061 
1998 1,006,170 6,904,231 
1999 1,117,967 8,022,197 
2000 1,242,185 9,264,382 
2001 1,380,206 10,644,588 
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6. Annual treatment costs per HIV infection by disease stage ($). 
 
Year HIV CD4 >500 HIV CD4 <500 AIDS 
1981 1,164 1,565 1,565 
1982 1,164 1,565 1,565 
1983 1,164 1,565 1,565 
1984 1,164 1,565 1,565 
1985 1,164 1,565 1,565 
1986 1,164 1,565 1,565 
1987 1,164 1,565 1,565 
1988 1,164 1,565 1,565 
1989 1,164 1,565 1,565 
1990 3,084 4,925 88,310 
1991 3,084 4,925 88,310 
1992 3,084 4,925 88,310 
1993 3,084 4,925 88,310 
1994 3,084 4,925 88,310 
1995 3,084 4,925 88,310 
1996 3,084 4,925 88,310 
1997 9,180 10,385 54,118 
1998 9,180 10,385 54,118 
1999 9,180 10,385 54,118 
2000 9,180 10,385 54,118 
2001 9,180 10,385 54,118 
 
 
7. Annual treatment costs per HCV diagnosis by disease stage ($). 
 
Stage 0/1 Stage 2/3 Cirrhosis HCC Liver Failure 
244 244 456 120,924 200,531 
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8. Estimated annual and cumulative cost/benefits of the NSEP ($) 
 
Lower bound estimates 
1988 0 0 0 0 0 -350,830 -350,830
1989 2,023 2,023 705 705 2,728 -387,083 -737,913
1990 4,837 6,860 6,858 7,562 14,422 -421,429 -1,159,342
1991 7,646 14,506 16,813 24,376 38,882 -456,788 -1,616,130
1992 10,509 25,015 33,782 58,158 83,173 -490,429 -2,106,559
1993 13,440 38,455 62,131 120,289 158,744 -518,562 -2,625,121
1994 16,484 54,939 107,619 227,908 282,846 -536,045 -3,161,166
1995 19,658 74,597 174,985 402,893 477,489 -538,855 -3,700,021
1996 26,642 101,238 274,698 677,590 778,828 -513,658 -4,213,680
1997 32,370 133,608 733,847 1,411,437 1,545,045 -139,336 -4,353,016
1998 39,764 173,372 1,057,454 2,468,891 2,642,262 91,048 -4,261,968
1999 47,404 220,776 1,499,161 3,968,052 4,188,828 428,599 -3,833,369
2000 55,333 276,109 2,092,732 6,060,785 6,336,893 905,880 -2,927,489
2001 65,742 341,851 2,873,779 8,934,564 9,276,414 1,559,315 -1,368,174
 
Year 
Annual 
HCV 
saving 
Cumulative 
HCV 
saving 
Annual HIV 
saving 
Cumulative
HIV 
saving 
Cumulative 
combined 
saving 
Total 
saving 
Cumulative 
total saving
1987       
1988 0 0 0 0 0 -350,830 -350,830
1989 7,780 7,780 2,710 2,710 10,491 -379,320 -730,150
1990 18,603 26,383 26,376 29,086 55,469 -388,145 -1,118,294
1991 29,408 55,791 64,667 93,753 149,544 -387,173 -1,505,467
1992 40,420 96,211 129,931 223,684 319,895 -364,369 -1,869,836
1993 51,692 147,903 238,965 462,649 610,552 -303,476 -2,173,312
1994 63,399 211,302 413,919 876,568 1,087,871 -182,830 -2,356,142
1995 75,607 286,910 673,020 1,549,588 1,836,497 15,129 -2,341,013
1996 102,468 389,377 1,056,529 2,606,117 2,995,494 343,999 -1,997,014
1997 124,498 513,875 2,822,489 5,428,605 5,942,481 2,041,434 44,420
1998 152,938 666,814 4,067,129 9,495,734 10,162,548 3,213,897 3,258,317
1999 182,324 849,138 5,766,005 15,261,739 16,110,877 4,830,363 8,088,680
2000 212,819 1,061,957 8,048,971 23,310,710 24,372,667 7,019,605 15,108,285
2001 252,853 1,314,810 11,052,996 34,363,706 35,678,516 9,925,643 25,033,928
 
Upper bound estimates 
1988 0 0 0 0 0 -350,830 -350,830
1989 13,538 13,538 4,716 4,716 18,254 -371,557 -722,387
1990 32,369 45,907 45,894 50,610 96,517 -354,860 -1,077,247
1991 51,170 97,077 112,521 163,131 260,207 -317,557 -1,394,804
1992 70,330 167,407 226,080 389,211 556,618 -238,309 -1,633,114
1993 89,944 257,352 415,799 805,010 1,062,361 -88,390 -1,721,504
1994 110,315 367,666 720,219 1,525,228 1,892,895 170,385 -1,551,118
1995 131,556 499,223 1,171,054 2,696,283 3,195,505 569,113 -982,005
1996 178,294 677,517 1,838,360 4,534,643 5,212,160 1,201,657 219,651
1997 216,627 894,143 4,911,130 9,445,773 10,339,916 4,222,204 4,441,855
1998 266,113 1,160,256 7,076,805 16,522,578 17,682,833 6,336,747 10,778,603
1999 317,244 1,477,500 10,032,849 26,555,426 28,032,926 9,232,126 20,010,729
2000 370,305 1,847,805 14,005,210 40,560,636 42,408,441 13,133,330 33,144,058
2001 439,964 2,287,769 19,232,213 59,792,849 62,080,618 18,291,972 51,436,030
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Appendix 6 - Glossary of terms and abbreviations 
 
BBV blood-borne virus (eg. HIV, hepatitis B, hepatitis C) 
Fit colloquial Australian and New Zealand term for a needle and 
syringe 
Harm Reduction Harm reduction is a public health approach that focuses on 
reducing the harm associated with certain behaviours (in this 
context, injecting illicit drugs).  The rationale is that injecting drug 
use is impossible to prevent, but potential consequences such as 
HIV transmission can be avoided or reduced in scale (by, for 
example, needle exchange programmes). 
Harm Minimisation While often used interchangeably with harm reduction, harm 
minimisation is in fact a much broader term that describes an 
approach to illicit drug use which encompasses supply reduction, 
demand reduction and harm reduction (in New Zealand, the term 
‘problem limitation’ is used instead of harm reduction).  Harm 
minimisation is the official policy of the Australian and New 
Zealand governments on illicit drug use. 
HBV Hepatitis B Virus 
HCV Hepatitis C Virus 
HIV Human Immunodeficiency Virus 
IDU injecting drug user 
Incidence the rate of acquisition of a characteristic (eg. HIV infection) in a 
population over time.  May be expressed as cases per 100 person-
years of observation, or per cent per annum 
NE Needle Exchange – one of 12 peer-based organisations which 
provides injecting equipment and associated services to people 
who inject drugs in New Zealand. 
NSEP Needle and Syringe Exchange Programme – the entire system of 
provision and collection of injecting equipment, which operates in 
New Zealand through NEs and pharmacies. 
NSP Needle and Syringe Program - an Australian term, used to refer to 
the entire system as well as individual ‘exchanges’. 
Peer Used throughout the report to refer to an individual who is a 
current or past IDU, typically working or volunteering in an NE 
Prevalence the proportion or percentage of a population having a particular 
characteristic (eg. HIV infection, ever using a shared needle and 
syringe) measured at one point in time. 
Problem limitation One of the three arms of New Zealand’s harm minimisation policy 
(alongside supply reduction and demand reduction), corresponding 
to the internationally-used term ‘harm reduction’. 
Returns used needles and syringes returned to an NE or pharmacy 
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Seroprevalence prevalence of virus exposure, as measured by presence of viral 
antibodies in blood samples 
STD sexually transmitted disease 
 
 
